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Abstract
Most research has been conducted on the structure and function of many individual genes as well
as complementary proteins. Many of these studies look at specific population country of
origin, geographic location, or ethnicity but do not correlate findings between these groups. In
this project I attempted to associate the structural and functional consequences of individual
mutations in Human BRCA1 to other organisms. My findings suggest a strong correlation
between human geographic isolation and mutation exclusivity. Furthermore strong sequence and
mutation conservation as well as structural homology exist between many species.
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Introduction
Breast cancer is the second leading cause of cancer death in women after lung cancer.
Every year 200,000 women and 1,000 men will be diagnosed with this disease in the US of which
approximately 40,000 will die (American Cancer Society, 2005). However these rates continue
to decline due to a combination of improved early detection and treatment techniques.
Although the exact cause of breast cancer is unknown, all cancers begin when a single
cell containing altered genetic material has disrupted normal cellular regulation. The result may
be lack of gene expression, increased cell death, or uncontrolled cell growth (cancer). There are
dozens of factors that may alter an individual's risk of having these mutations. Though not all-
inclusive, these may include age, race, smoking, family history / genetics, personal history, and
number of pregnancies. This project will focus primarily on heritage and genetic background
factors.
Symptoms of breast cancer can range from swelling and skin irritation to physically
noticeable lumps. Detection consists of routine clinical MRIs or mammograms accompanied by
self-examination. If a tumor is suspected, further x-rays may be taken and a biopsy performed.
The doctor may also perform staging tests to determine if the cancer has spread to other tissues.
Tests include PET, bone, and CT scans.
Breast cancer proliferates through direct invasion, lymphatic spreading or the circulatory
system. Direct invasion is characterized by when a tumor invades and destroys surrounding
tissue. Lymphatic spreading occurs when cells breaking away from the tumor are collected by
the lymphatic system and are deposited throughout the body. Similarly, the cancer may spread to
other organs via the circulatory system as tiny clumps or as individual cells break away. It is
unclear how a tumor grows, but it is known that surrounding blood vessels must infiltrate the
tumor for it to reach sizes beyond a few millimeters in diameter.
Treatment options are classified into either local or systemic categories. In the past,
surgery or localized radiation treatments were administered with broad based chemotherapy.
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Systemic treatments such as chemotherapy target any rapidly reproducing cells. Unfortunately
this leads to the destruction of both the cancer cells and other rapidly reproducing cells such as
blood producing bone marrow.
Recently, combinations of localized and ER-targeted systemic methods have become
more attractive as they inhibit carcinomas throughout the body. This allows simultaneous
treatment of all three potential spreading methods. Hormone supplements and immunotherapy
are two common forms of combined localized and systemic methods.
Cell growth and division is controlled by cell surface receptors and intracellular steroidal
hormone receptors in addition other growth factors (Osborne, 2004). Endocrine therapies block
estrogen-signaling pathways by lowering the amount of estrogen available for cell binding. A
systemic endocrine hormone treatment known as Tamoxifen (Tarn) is the most effective in its
class. Tamoxifen targets ER (estrogen receptor) positive breast cancer and is administered to
patients in conjunction with other therapeutic methods. However, many patients develop
resistance to this drug after prolonged use (Schafer, et al. 2002).
BRCAI - The Breast Cancer Gene
During the past decade numerous proteins and over 70 genes have been identified as
having links to breast, ovarian, and other reproductive system cancers. None is more famous or
studied than the BRCAI (BReast CAncer 1 / Breast Cancer type 1 Susceptibility Protein) gene
discovered in 1994 by Mary-Claire King at UC Berkeley (Friedman, 1994). A year later, a
second gene, BRCA2, was identified (Wooster, 1995). BRCAI is located at chromosomal locus
1 7q2 1.31, between NBR2 and RPL27 (Figure 1 ).
The original BRCAI gene was discovered after studying families with strong patterns and
histories of breast cancer. In each candidate similar mutations along chromosome 17 (Friedman,
1999) were noticed when compared to unaffected patients. After further studies it was concluded
that defects or mutations in BRCAI lead to an increased risk of developing cancers. Although
only 5% of cancer is related to a BRCAI mutation (Imaginis, 2006), the inherited risk for
developing the disease is as high as 40% (King, 2003). BRCAI is not limited to just breast cancer
but also associated with ovarian, cervical, and numerous other tissue cancers.
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Figure 1 - Map of BRCAI
Location of BRCAI on chromosome 17 between NBR2 and RPL17 in a strong CpG isle. Note upstream
duplication of BRCAI exons 1A, IB and 2 deemed BRCAIPI. (Source: NCBI MapViewer)
BRCAI and BRCA2 are known as tumor suppressor genes. BRCAI serves as a negative
regulator of cell growth (Thompson, 1995) by inhibiting cell growth in breast and ovarian cells
(Holt, 1996). Functional loss tends to put carriers at a higher risk of developing cancers but does
not guarantee cancer growth.
Frequent loss of heterozygosity (LOH) in both somatic and germline cells gave rise to the
theory BRCAFs tumor suppressor role (Geisler, 2002). LOH is the loss of one parent's
contribution and typically caused by large deletions in one allele. BRCAI inherited tumorigenesis
consist of a LOH combined with germline mutations in the other allele. Germline mutations
typically are small insertions, deletions or single base pair changes.
Since BRCAI resides on chromosome 17 it is inherited equally by both men and women.
BRCAI operates in a heterozygous manner, that is, a mutation in only one allele puts a person at
risk of the disease. It should be noted only the risk is inherited, not the disease.
Breast cancer is often accompanied by several other syndromes expressed in upstream
regulators of BRCAI . These include Li-Fraumeni (TP53 gene), Cowden Disease (PTEN gene),
Peutz-Jegher syndrome (STK1 1 gene), Ataxia-Telangiectasia (ATM gene). These syndromes are
caused by mutations in the individual genes and are not influenced by interactions with BRCAI.
Materials and Results
Research revealed a wealth of sequence, functional and mutation information available
for the BRCAI gene. This project was divided into three parts to study the conservation of
BRCAI. The first section investigated the biochemical functional aspects of the gene. Basic
physiological understanding provided a foundation for analyzing structural and functional
consequences resulting from mutations. The second section investigated sequence conservation
within the human species between different population groups. Extensive analysis on the
functional implications of mutations was studied and correlated between geographic populations.
Finally, I explored homology to other species looking at both protein sequence conservation as
well as functional repercussions, where available.
The PubMed archives in conjunction with the Oxford Human Molecular Genetics engine
were the two most valuable tools used during this project. The information gathered from these
sites was utilized as the basis of my research. To begin my research, I started with a NCBI OMIM
literature search to obtain an overview of current studies on the BRCAI gene. OMIM (Online
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Mendelian Inheritance in Man) is a hand edited catalog of human genes and associated disorders.
Searching on a particular gene or disease will result in an Entrez ID number along with a textual
brief. BRCAI for example is listed as +113705 and #114480 for the gene and disease,
respectively. Each brief is a combined overview of individual research articles. Many authors
have summarized article abstracts into a complete history, genetic information, animal models
and a few allelic variations. Full references including direct links to article abstracts are
provided. The publishing journal provides access to entire paper texts.
The NCBI site resources are very extensive causing disorientation first use. However,
after spending a few hours using these tools I discovered how powerful they were in mining the
vast amounts of data available for this project. The Entrez Database model gives a great
overview of how each NCBI database is cross-linked to other databases. A single NCBI database
entry is referenced to multiple other databases. For example, from an OMIN entry contains direct
links to the corresponding Entrez Gene entries.
Entrez Gene contains curated gene specific data from a variety of NCBI sources. Each
entry contains a summary of gene function, the reference DNA sequence, and interacting proteins
among other related sequence information. Entries also have link-outs to nucleotide, translated
protein, and transcripts (Unigene) sequences. Depending upon the type of gene entry selected,
one or more sequences will be available. I used this tool mainly for beginning my pathway study
of BRCAI interacting proteins.
To begin pathway research I used the BIND (Biomolecular Interaction Network
Database) provided by Unleashed Informatics. BIND is a collection of molecular interactions
between proteins gathered from NCBI literature sources. These basic interactions can be linked
together to form a molecular complex or pathway. Over 200k individual interactions have been
recorded through either hand curation or high-throughput screening methods. BRCAI has 170
molecular interactions and 15 complexes listed in the database.
Interactions are listed with number of domains to each molecule, exact binding sites and
the cellular binding location. This information was very useful in building a binding map used
during the mutation effect portion of my paper. Entries also contain link-outs to Pfam, GenBank
and several gene information sites like Swiss-Prot or UniProt.
Using a few simple text queries, I was able to identify about 200 possible protein
interactions on BRCAI. Of these, only a handful had site specific binding information available.
The remainder of protein binding predictions were based on conformation characteristics but not
backed by scientific data nor referenced in literature.
One problem I found with BIND is the number of duplicate entries. Although much of
the data has been hand-curated a fair amount is repetitious due to the automated submission
engine. I found myself consistently running across multiple entries for the same data and needed
to purge them from my results.
After using BIND, I turned my attention to the Human Protein Reference Database or
HPRD. HPRD is a platform for depicting protein domains, interaction networks and post-
translational modification substrates. Unlike BIND this site uses 100% hand extracted data so
information is deemed reliable. Searching for a particular protein yields a list of pictures
annotating binding domain position on the protein sequence. I preferred working with this site
over BIND as the binding sites and enzymes are presented in a more logical manor. The PTMs,
post-translational sites, are listed with upstream enzyme, reaction type and reaction site number.
This was very helpful for determining sites to monitor for mutation affects later in my research.
Gene Function
Perhaps the second most useful tool for studying the BRCAI pathway was Pathway
Studio and Medscan. Both are commercial packages from Ariadne Genomics created for the
extraction and modeling of biological pathways.
Pathway Studio is a software tool used for analyzing relationships between proteins, cell
processes, and small molecules to develop biological pathways visualizations. The tool has three
data input sources: 1) microarray data, 2) NCBI literature search, 3) and a proprietary database
named ResNet. ResNet is a precompiled database generated from scientific literature, public &
private data sources of signaling, and biochemical pathways using automated text mining tools.
For my study I used the second and third inputs.
For my first search I wanted to graph the diseases linked to BRCAI. A search on
'BRCAI"
in the disease database returns a list of eleven objects. Objects or
'nodes'
are physical
objects such as small molecules, proteins and complexes. Ten of these were proteins and one is a
membrane component.
Figure 2 displays the program's ability to generate a map of diseases related to the
BRCAI and BRCA2 proteins. To build the pathway some or all of the objects can be selected and
graphed. Based on my research, some of the objects listed are outliers not relating directly to the
BRCAI functional pathway. These include the proteins BCCIP and MRPL36 and the membrane
component M17S2. Selecting the remaining eight I built a shortest path graph which constructs
the shortest disease relationship between the entities. Between each node appears a
'control.'
Controls are actions such as expression, regulation, binding or other chemical reaction. As can be
observed in Figure 2, both BRCAI and BARD I have direct relationships to breast cancers.
Often graphing the shortest path will not build a useful pathway because the software is
aware that two proteins may require a small molecule to react. For example, ATR requires several
small molecules to react with BRCAI and therefore does not appear on many shortest path type
graphs.
I limited my search to return results with less than 100 nodes. This allowed plenty of
controls to understand the mechanics of the pathway but kept them to a manageable number.
Numbers larger than this tend to produce graphs that are extremely
'busy'
making them difficult
to read. As the number of components increases, the number of directed relationships grows
exponentially. In turn, this result in longer compute times for a complete pathway graph. These
would be useful for intricate studies but they are over complicated for my project. Figure 3 is a
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very broad search with 5 levels of depth. The resulting graph contains over 2000 nodes with
6500 controls leaving it essentially illegible without manual rearrangement of nodes.
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Figure 2 - BRCA1/2 Related Diseases
Diseases with linkages to BRCAI type breast cancer are pictured above. Many diseases link to both
BRCAI and BRCA2 while others are associated to only one gene. Graph created using ReNet database in
Pathway Studio Plus.
Medscan (Pathway Assist) is another Ariadne software package utilizing the same data
suite as Pathway Studio. This feature allows pathways to be built using a real-time scan of
PubMed abstracts. Medscan is able to create pathways by extracting information from article
abstracts using a proprietary dictionary to build relations between proteins.
Since the BRCAI pathway is still under investigation neither tool is able to build a
complete pathway. However, they are ideal for building detailed partial pathways. For example,
the relationship between BRCAI and the RAD50-MRE11-NBS1 complex can be quickly graphed
as shown in Figure 4. This gives a basic understanding of the regulators and responsibilities. The
original article abstracts can be obtained in Medscan by clicking on the various picture
components such as proteins or actions.
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Figure 3 - BRCAIPathway
Directed graph of 2000 proteins (nodes) with published paper relationships to BRCAI . BRCAI is centered
with surrounding proteins interacting directly with gene. Created using Pathway Studio Plus.
The last tool included in Pathway Studio is Pathway Reference Summary. This tool
builds a bibliography page based on reference sources in the current pathway. This file is
generated from either the ResNet database or live Medscan results depending on the original
search type.
BioCarta and Protein Lounge proved to be useful tools for building the BRCAI pathway.
Protein Lounge contains one of the largest graphical pathway and protein interaction databases
available on the internet. Although the site is a subscription based service they do offer limited
trial accounts. BioCarta Pathways is a free service provided by a partnership between the
National Cancer Institute and BioCarta Inc.
Both sites contain very similar information and pathway mapping diagrams. Pathways
are displayed as an image map accompanied by a large discussion of major interactions. Each
protein in the pathway is linked to detailed information including an NCBI Online Mendelian
Inheritance in Man (OMIN) style review, sequences, other family proteins, and full publication
lists. The Protein Lounge pathways usually contained more proteins per diagram making them
appear more complete. These 'extra' proteins are often associated with reactions not directly
related to the main pathway.
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Figure 4 - BRCA1-MRE1 1/Rad50
A portion of BRCAI regulation and function ofMRE 1 1-Rad50 graphed in Pathway Studio. Notice
BRCAI upregulates MRE1 1 and blocks the FANCA response pathway.
Protein Structure
Sequence and structure data was gathered from sources such as GenBank, Entrez
Protein/Structure and the PDB. Similar to before, PubMed articles were used as a reference to
isolate bonding sites and special structural features. Swiss-Prot and Entrez Protein contains
translated sequences along with publication references. Both sites summarize gene function,
disease relations, and domain subunits. Swiss-Prot is more of a one-stop shop for information on
genes. In addition to sequence information they also provide 3D structure links, interaction
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databases, 2D SDS (gel) samples, and a detailed feature table. The feature table charts the
position of two-dimensional conformations such as helices, strands and turns. I utilized this
resource to test my predicted protein models.
Entrez Structure is a molecular model database of 3D protein domains. Entrez structure
contains two types of models. First each entry is linked to the RCSB (PDB) structure model.
RCSB models are formed from predictive computational methods, X-ray crystallography and
NMR. RCSB formatted files are an open standard that is widely accepted by a variety of
modeling software.
Second, Entrez contains ASN.l formatted structures stored in MMDB (Molecular Model
Database). These are derived from RCSB entries but eliminate hypothetical models, sequence
fragments and isoforms. Entrez files are processed specifically to enhance the chemical integrity
of models in preparation for computational manipulation. MMDB files are readable in a NCBI
utility called Cn3D. Cn3D provides basic rendering functions and the ability to highlight
domains. It does not allow modifying the model or the ability to predict structural transforms.
To determine structure & bonding functionality, I observed the C-terminal models of
1 JNX and XRCCI ( 1CDZ). 1JNX is the crystal structure of the BRCT repeat region. XRCC1 is a
DNA repair gene containing a domain similar to the BRCAI C-terminus. Slight differences
between these models were useful for observing structural changes induced by sequences
mutations. At the RING domain, I used the 1IM7 model which is a heterodimer formed by
BRCAI bound to BARD1. All three models were viewed in Cn3D and QuickPDB but final
rendering was completed in MolScript.
MolScript is a powerful tool used for rendering and manipulating 3D images from PDB
files. Although the program is command line based, an OpenGL viewer is included for
conducting real-time visual manipulations. The power behind this program results from the
ability to highlight important molecules, forces and bond angles. All tweaking and manipulation
must be done via the input file prior to rendering. Table 1 includes a portion of the script used to
render 1JM7 PDB files in MolScript.
To render the BRCAI RING domain I used the Entrez Structure model 1IM7 - Solution
Structure of BRCAI-BARD1 RING-domain Heterodimer. As no standalone BRCAI RING
models are available, this was the best choice as it contains mutations-free sequences.
The C-terminal repeats were modeled using 1INX - Crystal Structure of the BRCT
Repeat Region. This model contains both repeats allowing access to the dimer interface where
CtIP and BACH1 bind.
While using this program I encountered several problems. The first being it only is
available in a precompiled format for IRIX. Machines capable of running this software are
outdated and often difficult to locate.
My first model was the RING domain using 1IM7. Molscript automatically renders all
models described in the input PDB files. Since 1IM7 is a solution prediction and not an exact
crystalline structure, several theoretical models are presented in the PDB database. When
rendered, all of the models are displayed concurrently (Figure 5). Variability exists mostly in the
loops with well defined helix and sheet positions. To correct this problem I edited the PDB file to
only include a single model.
My second issue was some beta sheets were not rendering properly. Since the strands in
1JM7 are usually only 2-4 residues in length, the PDB file had mistakenly labeled them with a
sheet identifier. To correct this I edited the PDB file specifically defining beta sheet start and
stop positions. Other models such as 1INX were visually accurate and only required minor
tweaking along the beta sheets.
1INX was an easier model to render since the PDB information is more concrete. The
only major problem I encountered was a
'fused'
beta sheet. Two beta sheets had fused as the
PDB file did not correctly identify turns connecting the sheets. This resulted in three beta sheets
instead of four. In this case the PDB file contained correct information but a bug in Molscript
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caused a strand skipping. To correct this issue the Molscript input file was changed to realign
four parallel beta sheets.
Figure 5 - NMR Predictions of 1JM7
Entrez NMR models of BRCAI 's RING domain contain moderate variability in the cross-over loops and
placement of Zn+ atoms. The above Molscript visualization uses stock input data to illustrate the
variability in the input file.
My final step using Molscript highlighted the four major bonding sites in the RING-
BARD molecule. To do this, I programmed Molscript to select the sidechains of specific
backbone residues in the upper helixes. Bond lines were then added between the sidechains of
opposing molecules.
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Table 1 - MolScript sample input for 1JM7
MolScript renderings are computed from two input files. The first is a script containing the location of a
PDB formatted tile and the location of areas of interest. Areas of interest may be he lices, stands, or
individual residues. A portion of the script used to create the rendet ing in Figure 5 follows
shadows on;
window 61.38;
slab 3 2.30;
read mol " 1JM7- 1 ;
transform atom *
by centre position atom *;
set segments 2
# Set color and coordinates of first Alpha Helix
set planecolour hsb 0.6667 1 1;
coil from Al to A7 ;
set planecolour hsb 0.6275 1 1;
helix from A7 to A22;
# Set color and location of sidec lain molecules .
set colourparts off;
set planecolour white;
ball-and-stick require in residue A7 and backbone ;
ball-and-stick in residue A10
ball-and-stick in residue A85
ball-and-stick in residue A96
Structure/Functional Mutations
To begin mutation research another thorough search of literature was undertaken to
determine well-know mutations and exons of interest. Individual mutation sites and effects were
obtained from the Universal Mutation Database, Cancer Genetics Web, Human Gene Mutation
Database and the Breast Cancer Gene Database, in addition to individual journal articles. Using
this information modified sequences were submitted through prediction programs then modeled
by DeepView, Molscript or Compare3D.
The NIH Breast Cancer Information Core database is based off of GenBank BRCAI
standard U 14680. This database was crucial in locating polymorphisms throughout the gene and
also specific protein binding sites. The total number of mutation entries is approximately ten
thousand. However, only 1500 unique entries reside in the database with 658 mutations reported
more than once. Shockingly, only 82 of all mutations in this database are cited as published in a
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periodic journal. This lack of published studies has not diminished the database popularity
among researchers.
Although the NIH database is easy to navigate, it only permits simple data searches and
does not allow more complex statistical queries. However, a raw data dump of the entire
database is available. After downloading the complete dataset, I attempted to load it into a local
SQL repository. Unfortunately due to frequent data type violations and syntax mistakes the data
did not easily load. Commonly, the wrong data was placed in a column or combined with
adjacent data cells. Additionally, mutation designations and position naming conventions differ
widely. For example, a single base-pair deletion may be written as del A, delA, or del-A.
Similarly intron mutations are named 'intronic', 'Non-coding', 1-20, or 'intron/spf. These
variations make data mining difficult without first normalizing the dataset. The variations may in
part be due to the broad naming standards available at Human Genome Variation Society
(Dunnen, 2000). After some modest hand curation and automated massaging the data was bulk
loaded using a custom shell script. My local dataset was taken from lune '05.
After working with the dataset for several months, I have some general concerns about
the completeness of the database. As with any of the publicly available databases it is the
responsibility of researches to submit information. 1 question the accuracy of statistical numbers
derived for high frequency mutations. For example, the frequently occurring 185delAG mutation
was reported over fifteen-hundred times.
When compared to other mutations is this an accurate occurrence rate of the mutation in
the general population? I hypothesize the submission rate for a non-unique mutation is inversely
proportional to the number of existing entries for that mutation. People are more likely to report
new scientific finds but not information already discovered by another researcher. A prime
example of this is the second most frequent mutations 5382insC. As a mutation with such a high
incidence rate, I find it odd it was last reported in 2003.
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Once the data was loaded into my local database I was able to launch queries against it.
Table 2 outlines some SQL commands used to query the dataset and the composite result.
Table 2 - SQL Queries for BIC Database
Data from the BIC database was queried using standard SQL (Structured Query Language) after loading
the dataset into a relational database, (a) Query for finding the number of mutations per exon. (b) Query
for determining the number of mutations between codon 1528 and 1862 that are located in exons. (c) Query
to determine quantity of each mutation type with results displayed in (d). Mutation type abbreviations (e).
(a)
SELECT exon, count (exon) FROM brcal_db GROUP BY exon ORDER
BY exon ;
(b)
SELECT count (*) FROM brcal_db WHERE '1528' <= codon AND codon
<= '1862' AND exon NOT LIKE '%!%';
(c)
SELECT mutation_type, count (*) FROM brcal_db GROUP BY
mutation_type ORDER BY count DESC;
(d)
mutation_type | count
(e)
Abbreviation Mutation Type
F Frameshift
IFI In Frame Insertion
IFD In Frame Deletion
M Missense
N Nonsense
P Polymorphism
S Splice
Syn Synonymous
UV Unclassified Variant
My first task was to profile the number of mutations in each exon of the gene. This was
done simply by counting the number of mutations per exon (Table 2a). Next I queried for
mutations in each protein domain listed in Table 6. This query was limited to coding regions by
removing introns with the
'I'
flag (Table 2b). Finally, I queried for the most frequent mutation
types and the most frequent mutations. Introns were included in both of these searches (Table
2c).
To search for the most frequent mutation locations in BRCT I trimmed the mutated
amino off each mutation. For example, R1699Q and R1699Q were truncated to simply R1699
(Table 4).
Table 3 - Most Frequent Mutations in BIC Database
SQL to determine the top 15 frequently occurring mutations including mutations in introns.
SELECT designat ion, countf*) FROM brcal db GROUP BY designation
ORDER BY count DESC LIMIT 15;
designation count
185delAG | 1596
5382insC 836
C61G 155
IVS5-11T>G 152
R1347G 149
R841W 114
M1008I 105
4184del4 105
R1443X 103
3875del4 97
IVS21-36del510 80
IVS2-14C>T 77
E1250X 76
Q563X 70
M1628T 70
Table 4 - frequent Mutations in C-terminus
SQL to determine the top 20 mutations occurring in the BRCAI C-terminal region.
SELECT exon, designation, count (*) FROM brcal db WHERE
exon = ' 16 '
OR exon = '17' OR exon = '18'
OR exon = '19' OR exon = '20'
OR exon = '21' OR exon = '22'
OR exon = '23' OR exon = '24'
AND v 1646' < codon AND codon < v 1856'
GROUP BY exon, designation ORDER BY count DESC LIMIT 20;
exon designation count
20 5382i 837
24 R1835 | 51
16 M1652 j 42
18 A1708 j 39
16 5083d j 38
19 5296 j 30
20 R1751 | 29
21 M1775 1 23
18 R1699 j 20
22 G1788 j 19
20 G1738 ! 15
17 5149d | 15
18 Y1703 | 14
18 5256d | 14
24 W1837 j 13
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Since the BIC site does not provide tallying tools, it was relatively easy using SQL to
find the population with the most mutations (Table 5). Some of the problems with non-standard
data submission are visible in the table on the left. The table on the right shows the data after a
cosmetic review. Note the first line is blank yet has a 3616 total. These are entries without an
ethnicity defined. Also notice the multiple occurrences of Western-European, Western Europe,
and Western European.
Table 5 - Populations with High BRCAI Mutations
Mutation count varies among population groups. Since the BIC database does not standardized naming
conventions, multiple ethnic groups often appear in results. Notice the duplication ofWestern European
and Not Specified in the left table. The table on right was hand modified to contain only one row per
population.
SELECT ethnicity, count (*) FROM brcal^db GROUP BY ethnicity
ORDER BY count DESC LIMIT 11;
ethnicity count ethnicity count
| 3616 None Specified 4540
Ashkenazi 1171 Ashkenazi 1334
Western-European | 1098 Western -European 2299
Caucasian 671 Caucasian 213
None-Specified 586 African 159
Western Europe 494 Central/Eastern European 246
Not Specified 267 Latin -American/Caribbean 173
Western European 265 Greek 86
None Specified 243 Asian 104
African 1 157 African American 77
Central/Eastern-European 110 (10 rows)
(11 rows)
Mutation effects on structure were studied using a combination of predictive modeling
tools. Mutations at bonding sites and those mentioned in the literature were submitted into these
forecasting programs. The first program I used was called Protein Predict.
Protein Predict (PHD) is web-based tool for predicting secondary structure from
nucleotide or amino acid sequences. The power of this program comes from combining many
separate prediction programs and algorithms. Each program analyzes a different portion of the
protein structure such as amino-acid chain interactions, solvent accessibility or sequence
alignment. Each of the results is scored with a confidence level identifying the accuracy of the
prediction. Users can then assess the most reliable prediction method for the protein sequence.
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Output from Protein Predict is presented in a graphically formatted HTML display of alignments,
tabular charges, and probable structures.
Protein Prediction appears to make better predictions for sequences with multiple
mutations rather than single nucleotide polymorphisms. I suspect this is due to SNP sequences
sharing significant homology to a single known sequence. When multiple mutations are
introduced, the prediction algorithm is able to calculate results from many partial models rather
than a single input.
For my research PROsec and PROacc from PHD were the most useful and accurate for
analyzing novel mutations in the RING and BRCT domains. PROsec focuses on secondary
structure prediction using multiple sequence alignment. PROacc predicts solvent accessibility of
residues using a neural network of 238 standardized proteins. Selective output from Protein
Predict allowed submission to third party sites such as Expasy Swiss-Model.
Swiss-Model is a protein modeling service provided free by Swiss Institute of
Bioinformatics. Swiss-Model works by first using BlastP2 to search for similar target sequences.
Sequences with identity above 25% are superposed on homologous areas of known models.
Unknown or mutated areas are then modeled by using known Phi and Psi angles from a database
of known fragments. The modeled structures are then checked against another database of known
sidechain rotamers. The final model is verified using the Luthy method (Luthy, 1992) for
assessing protein model quality.
Swiss-Model generates a PDB file based on either raw sequences or Swiss-Prot accession
numbers. I found the models generated were generally accurate predictions of both actual PDB
entries and documented conformation changes.
Conservation
To find conservation between both human protein samples and other species PSI-
BLAST, RPS-BLAST, ExPASy and CDART were used to find sequence variants. All of these
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tools accept standard FASTA formatted files. Selective sequences from these programs were
combined for comparison in ClustalW or ScanPS (protein).
ClustalW is a multiple sequence alignment tool for protein or DNA. Window, gap, and
matrix (BLOSUM vs PAM) alignment are adjustable among other parameters. Output from
ClustalW is given in a plain text format to be read by lalView. JalView (Java Alignment editor)
as the name implies is a program for viewing the alignment output from ClustalW (Figure 6).
As each of these programs is hosted at a different site, a moderate amount of work is
required to search, align and edit the results. However, the effort is worth the ability to visualize
and manipulate the alignment. Sequences can be quickly colored along BLOSUM score, percent
identity, strand/turn/helix or other scoring methods.
# http://www.ebi.ac.uk/cgi-bin/jobresults/clustalw/clustalw-20060531-02543712.aln
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Figure 6 - ClustalW Alignment
A sample protein sequence alignment displayed in ClustalW with conserved amino acids distinguished in
different colors.
CDART (Conserved Domain Architecture tool) returns sequence and structure/function
homology matches. The database backing CDART is based on alignments of partial and full-
length protein domains. CDART uses RPS-BLAST engine to find matches but then compares
pre-computed scores on the domain to determine a final match.
Conservation in Other Species
Finally, I explored sequence and function homology in other species such as mouse
chromosome l l and Drosophila using similar BLAST methods and tools as outlined above. In
addition to the typical homology search tools I found MGI (Mouse Genome Informatics) and
BLink very useful.
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The MGI website was an invaluable tool for understanding mouse genomics and the
relationship to the human gene counterpart. Searching for an individual gene reveals a sequence
summary report. For mouse, six potential sequence matches were listed, four correlating to
BRCAI . Each gene detail report is a one-stop shop for all information associated with the mouse
gene. Of particular use were the genetic map, sequence map, protein domain and mammalian
homology sections.
In addition to the NCBI MapViewer, the MGCI Sequence Map highlights the Mouse
BRCAI gene location in four different viewers - Vega Mouse, Ensembl, and the UCSC genome
browser. All of these tools were very good at detailing the position of the gene in relation to
other genes on the chromosome.
The mammalian orthology section of MGI contains direct links to the Entrez Gene
reference sequences used to map homology. Mouse BRCAI had three verified homologous
domains with human, rat and domesticated dog DNA.
The other tool to hunt for related sequence data was BLink (BLAST Link) at NCBI.
Each Entrez Protein stored in NCBI has an associated BLink entry. These entries contain
graphical lists of previously recorded BLAST searches. Similar to blast results the list contains a
score, p-value along with accession and organism name. They are somewhat easier to read than
BLAST results since the FASTA output is omitted.
Gene Function
DNA mutations frequently leading to cancerous cells are caused by ionizing or ultraviolet
radiation, environmental chemicals, or cellular respiration products. Cells, but particularly
genomes have adapted mechanisms to specifically deal with these types of alterations. As the cell
cycles through its normal metabolic pathway, checkpoints and DNA repair mechanisms are
constantly at work. Some of these mechanisms are so important they are literally integrated into
the cycle, not just
'complementary'
side actions. Repair pathways must not only sense damage
signals, but the type of damage, timing of cell cycle, and location of damage.
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Proteins involved in the damage response pathway are grouped into sensors, transducers
and effectors. BRCAI participates in a global role in DNA-damage response, though the process
in its entirety is still unknown. It contains key effectors regulating damage-induced arrest in all
cell phases. Its role in meiosis is associated with double-strand break repair, homologous
recombination (Chen, 1999), and nucleotide excision repair. More specifically, it regulates
critical phase transitions by controlling expression, phosphorylation and cellular localization of
cyclin-dependent kinases among other proteins (Yarden, 2002). Through these mechanisms it
reduces the sensitivity of cells to double-stranded DNA breaks generated by exposure to infrared
and gamma radiation.
BRCAI is found within a "large multisubunit protein complex of tumor suppressors,
DNA damage sensors and signal
transducers" deemed BASC (BRCAI associated genome
surveillance complex) (Wang, 2000). Proteins of this complex are crucial for recognizing DNA
damage, abnormal DNA and triggering repair. BRCAI interactions occur with over 25 different
proteins with major reactions occurring with NBS1 (Nibrin), RAD50-MRE1 1 (Meiotic
Recombination- 1 1), and ATRIATM (Ataxia-Telangiectasia) and BARD1 (BRCAI -Associated
Ring Domain-1). [See Table 6 for a complete list of these proteins]. ATM and ATR are
considered both sensors and transducers. Chkl and Chk2 are transducers while Cdc25 and other
CDKs (cyclins) are effectors (Lee, 178).
BRCAI is a nuclear phosphoprotein associated with the ubiquination of RNA polymerase
II, FANCDI and other kinases. It is implicated in the transcriptional regulation of DNA damage-
inducible genes that function in cell cycle arrest. BRCAI is located predominantly in the nucleus
and perinuclear compartment of endoplasmic reticulum complex (Paull, 2001) with the greatest
levels found during S and M phases (Chen, 1999).
Although the exact protein function has not been established it plays an active role in
transcription regulation, chromatin remodeling, mRNA processing, cell cycle checkpointing and
apoptosis. Most importantly BRCAI controls checkpointing between G2 to M phase of the cell
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cycle (Figure 7). During this period its two responsibilities are participating in detecting
damaged DNA and responding and repairing it. (ProteinLounge, 2006).
Table 6 - BRCAI Related Proteins
Over 25 proteins interact directly with BRCAI at one or more binding sites. Specific binding sites are not
known for all proteins but general regions have been identified. BRCAI polymorphisms are found in
uniform frequency across the entire genomic region. Binding data compiled from the Biomolecular
Interaction Network Database (BIND) and mutation information from NCBI Breast Cancer Information
Core (BIC).
Protein BRCAI Codon Binding Site BIC mutations Citation
CDC2 1-76 1981 (Wang, 2000)
CDK2 1-76 (Wang, 2000)
BARD1 1-103 Arg7, GlulO, Glu85, Asp96 1981 (Brzovic, 2001)
Znl + 1-103 Cys24. ILE26, Cys27, Cys44. Cys47 (Brzovic. 2001)
Znl + 1-103 Cys39. His41, Cys61, Leu63, Cys64 (Brzovic, 2001)
ER-alpha 1-306 Alal708, Metl775.Tyrl853 2249 (Kawai. 2002)
p53 224-500 Exon 1 1 776 (Zhang, 1998)
P53 1760-1863 Unidentified sites in BRCT (Chai. 1999)
Rad50 341-758 1162 (Zhong, 1999)
ATR 521-757 Serl423, Serl457, Serl524 582 (Gatei, 2000)
ATM 751-1070 (Gatei. 2000)
ATM 1241-1530 Serl 189, Serl387, Serl423, Serl524 (Gatei, 2000)
FANCA 740-1083 1269 (Folias. 2002)
Rad5 1 758-1064 Exon 1 1 1221 (Scully, 1997)
CDK2-A/E 1497 Serl 497 (Ruffner, 1999)
BACH1 1429-1863 Serl655,Glyl656, Lysl702 226 (Cantor, 2001)
CK2beta 1460-1653 542 (O'Brien. 1999)
TRAP220 1528-1863 Argl708, Pro 1749, Met 1775 1945 (Wada, 2004)
CtIP 1603-1863 Serl655, Glyl656, Lysl702 1772 (Wong, 1998)
The proteins produced by BRCAI bind strongly to DNA allowing it to promote the
activities of the MRE1 1IRAD50INBSI complex that is used for double-strand break repair. Loss
of this ability contributes to "profound instability (Mallery, 2002), spontaneous
DNA breaks and ultimately tumorigenesis(Fan, 1999). BRCAI interacts with several other genes
to carry out these vital functions including ATR, Chk2, and RAD51.
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Figure 7 - BRCAI Phase Checkpoints
BRCAI's role as a sensor, effector, and transducer combine to support tumor suppression and DNA repair.
Gl Phase
Gl phase is marked by cell growth and preparation for chromosomal replication.
Damaged DNA evading this period may severely affect future cell processes and possibly be
inherited by other cells leading to cancers. During this phase, DNA is checked repeatedly for
mutations in an effort to maintain genetic integrity. This paper will focus explicitly on detection
and repair mechanisms of double strand breaks caused by IR and UV radiation.
Double stranded breaks (DSB) are the most cytotoxic lesion (Protein Lounge, 2006)
leaving both backbone strands disconnected. DSBs are repaired in both pre and post-replication
stages using either direct joining or homologous recombination (HR) methods. Direct joining
ligates exposed ends with little matching logic so massive translocation errors often result. HR
on the other hand uses information intact on sister chromatids, homologous chromosomes or the
same chromosome to correctly pair disjoined segments.
Genotoxic stress from double-strand breaks trigger a cascade of protein reactions
controlled by the BRCAI gene. BRCAI damage and repair pathways are invoked through initial
stimulation of ATM and ATR proteins. In response to UV (ultraviolet) and HU (hydroxyurea).
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two agents interfering with replication, replication proteins recruit ATR to damage sites (Zou,
2003). Emergence from Gl phase is dependent upon the Gl/S checkpoint invoked by ATM.
Double strand breaks are detected as the cell emerges from Gl phase through
phosphatidylinositol kinase proteins (ATM I ATR) and cycle arrest occurs by blocking cyclin-
dependent kinases. ATM and ATR present at the replication fork are activated upon DNA damage
resulting in phosphorylation of numerous substrates (Liu, 2000). ATM and ATR are involved in
multiple parallel but redundant pathways responding to different DNA stresses (Andreassen,
2004) such as double strand breaks or replication forks (Figure 8). One pathway involves the
detection of DNA damage and cell cycle arrest while others are responsible for repair.
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Figure 8 - ATM-ATR Damage Response Pathway
In response to Ultra-Violet or Ionizing Radiation. ATM and ATR function in parallel pathways to up-
regulate a damage-response pathway. Cyclin-dependent kinases, Chkl & Chk2, are phosphorylated by
ATMIATR after exposure to DNA damaging elements. These genes operate in a redundant manner to
ensure both cell cycle checkpoints and repair mechanisms are synchronized.
In response to ultraviolet or ionizing radiation damage, Chkl phosphorylates p53 (Banin,
1998) in an ATM dependent manor. p53 is a protein transcriptor mediating other damage-
response proteins the damage response (Coene, 1997). p53 phosphorylates activator p2I causing
a Gl arrest by inhibiting transcriptionally regulated cyline dependent kinases CDK2 I cyclin-E
and CDK4 I cyclin-D (Waldman, 1995). The stalled replication fork is stabilized by additional
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p53 phosphorylation through Chk2 (Chehab, 2000). Higher levels of damage trigger immediate
apoptosis through ATM blocking p53 activity and directly phosphorylating BRCAI -cAhl. If
necessary, c-Abl induces cell death by activating or blocking cell survival proteins p53,
JNK/SAPK, or p73 (Sordet, 2003). ATM-p53 induced apoptosis may also occur at any point in
the cell cycle.
Under normal conditions, BRCAI C-terminal region binding regulates tyrosine kinase
activity of c-Abl. IR conditions invoke ATM phosphorylation of the BRCT region causing
disassociation of this complex resulting in increased tyrosine activity (Foray, 2002). The cleaved
BRCAI surface makes room for binding of other proteins such as BACHI and CtlP.
S Phase
In preparation for repair, dramatic increases in BRCAI expression at the onset of S-phase
are accompanied by the accumulation of BARD1 polypeptides into nuclear dots in the
endoplasmic reticulum (lin, 1997). BARD1 (BRCA /-Associated RING domain-1) is a protein
sharing homology with both C and N-terminal regions of BRCAI. It's effectiveness at
maintaining genomic integrity through Rad5I mediated single-strand exchange and homologous
paring (Jin, 1997) classify this protein as a tumor suppressor (Wu, 1996). A BARDI deficiency
results in uncontrolled cell growth whereas overexpression results in cell death (Irminger-Finer,
2001). Typically found during S phase but not during Gl (Jin, 1997) its product peaks with the
onset of DNA synthesis. Low levels of BRCAI -BARD 1 complex during Gl phase act a p53
adaptor for ATM phosphorylation (Fabbro, 2004). Hyperphosphorylated BARDI predominate
during M-phase / mitosis (Choudhury, 2005) for nuclear retention of BRCAL controlling
chromosomal euploidy and homology-directed repair. Additionally, it is another p53 mediator of
apoptosis (Wu, 1996).
After the cell is arrested, the DNA repair pathway is put into action. At the same time
repair is occurring another parallel pathway will continue regulating the cell cycle. These
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pathways are kicked off by ATM or ATR phosphorylation of at least six proteins including
BRCAI, BRCA2, Rad51, NBS1, Chkl, and Chk2.
ATR induced phosphorylation of BRCAI is considered the beginning of the repair
pathway. Phosphorylation at this point forks separate pathways for phase control and repair.
DSB activation oi ATM triggering p53 arrest begins the two additional parallel pathways for S-
phase checkpoint delay eventually intersecting at FANCD2 (Falck, 2002).
ATM (or ATR (Pichierri, 1995)) phosphorylizes NBS1 to produce an S-phase checkpoint
delay (Xu, 2001). Failure to invoke the S-phase checkpoint will result in uncontrolled DNA
synthesis (Xu, 2001). NBS1 later forms with MRE1 1-Rad50 heterotetramer to control the repair
process and regulates phosphorylation of FANCD2.
G2 phase
BRCAI is required for both S-phase arrest and G2/M phase checkpoints (Xu, 2001 ). Gl
activated Chkl and Chk2 target different BRCAI molecules for control of G2 phase checkpoints
through ATM and ATR respectively (Yu, 2004). Although Chkl and Chkl are responsible for
G2/M arrest through different regulators, both mediate the same cyclin-dependent kinases
(Cyclin-B and Cdc25C). BACH1 (BRIPI) and CtlP (CtBP interacting protein) are the two
proteins controlling these pauses which bind at the same BRCAI C-terminal region but are
managed differently.
The BRCAI BRCT domain directly interacts with phosphorylated BRCAI -associated
carboxyl-terminal helicase (BACH!) (Yu, 2003). BACFII forms a heterodimer functioning as a
transcription activator or repressor along with the transcriptional corepressor CtlP (Varma, 2005).
BRCAI -BACH1 interaction is cell cycle regulated with the association persisting from S through
M phase and required for DNA damage-induced checkpoint control (Yu, 2003). BACH1 plays a
catalytic role in double strand break repair through it's mediation of ATR (Cantor, 2001). In
response to IR and other stimuli, ATR rapidly phosphorylates Chk2 stimulating Chk2 kinase
activity (downstream signal transmission) (Huberman, 2005). Chkl modulates BRCAI function
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in response to DNA damage through phosphorylation serine-988 (Lee, 2002). Release from this
serine site allows cell cycle restoration. Subsequent hyper-phosphorylation of BACH1 by ATR
and Chkl promotes homologous & non-homologous recombination (Choudhury, 2005) leading to
a G2 "accumulation checkpoint". Prolonging G2 phase postpones mitosis while the cell DNA is
still damaged (Figure 9).
While the BRCA1-BACH1 association persists from S to M phase, BRCAI-CtlP is far less
stable only existing during G2 phase (Yu, 2004). CtlP is another C-terminal interacting protein
which binds in place of c-Abl at the BRCT repeats. CtlP is phosphorylation-dependent for
binding to BRCT domains during early G2 (Yu, 2004).
CtlP is phosphorylated again in late G2 phase while bound to the BRCAI repeats. Direct
phosphorylation by ATM causes a hyper-phosphorylated CtlP to disassociate from BRCAI . ATM
phosphorylates CtlP at Serines 664 and 745 (Li, 2000). Release from CtlP allows BRCAI to
activate Chkl to induce the G2/M transitional checkpoint (Yu, 2004). Mutations in the CtlP
binding region have significant implications such as repression of BRCAI induction of GADD45.
BRCAI activation of GADD45 in conjunction with p53v from Gl phase support
transcriptional regulation behavior (Jin, 2000). GADD45 is targeted by both BRCAI and p53p
through a complex method not fully understood. However, it is believed BRCAI represses
GADD45 through interaction with ZBRK1 (Fan, 2002) and various other transcription factors.
Although p53 is not required for GADD45 activation, it factors into the strength of the response.
CtlP is an upstream repressor of GADD45 expression through a BRCAI dependent manor
(Figure 9). Release of CtlP from BRCAI allows BRCAI to also regulate GADD45 (Fan. 2002).
GADD45 (Growth-Arrest and DNA-damage) gene is considered a DNA-damage response gene
because of its damage induced up-regulation and ability to arrest cell cycle (Li, 2000).
GADD45's main function is to cause G2/M arrest thereby suppressing cell division. GADD45
may also play an indirect role in BRCAI induced apoptosis via JNKISAPK activation (Scheikh,
2000). The G2/M checkpoint delays transitioning into mitosis allowing time for DNA repair.
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Failure to stop at this point allows progression of chromosomal rearrangement with damaged
DNA resulting in lost genomic integrity.
Approaching the G2/M checkpoint Cdkl (Cdc2) levels increase steadily during S phase
(Jin, 2000). CDK (cyclin dependent kinase) promoters control phase progression. Blockage or
inhibition of these proteins stalls phase transitions otherwise known as checkpoints (Jin, 2000).
GADD45 inhibits entry into M-phase through Cdc2 (Cdkl)/ cyclin-B inactivation until repair and
transcription are complete. GADD45 modulates this checkpoint by blocking the Cdc2-cyclin-B
kinase complex (Yang, 2000). Cdc2 is a protein phosphatase initiating DNA synthesis and
mitosis. Expression, phosphorylation and cell localization of Cdc2 & Cdc25C are controlled
explicitly by BRCAI in G2 phase. GADD45 does not phosphorylate Cdc2 but instead binds
directly to it.
This checkpoint works in conjunction with the parallel CtlP-Chkl induced control of the
same Cdc25C pathway. Prior to G2, the Wee I kinase adds an inhibitory phosphate to Cdkl
rendering the kinase inactive (Harvey, 2005). Upon release from GADD45, Cdc2 removes this
phosphate. Subsequent Chkl phosphorylation of Cdc25C promotes the binding of 14-3-3
regulatory proteins (Brown, 1999).
Chk2 has been implicated as a backup phosphorylation agent of Cdc25C in the absence of
Chkl (Liu, 2000). Both Chkl and Chk2 block Cdc25C in similar manors and functions
controlling cell cycle checkpointing, transduction of DNA damage, and replication stress signals
(Brown, 2002). Significant overlap, coordination, and redundancy are exhibited in this pathway
to ensure DNA integrity.
GADD45,s other behavior is to stimulate DNA excision repair through Rad51 (Smith,
1994). Upregulation of RAD5 1 promotes DNA strand exchange during homology-directed repair
(HDR) ultimately leading to chromosomal integrity (Foray, 2002). BRCAI and BRCA2 also
participate in direct activation of Rad51. Initial ATM phosphorylation of BRCAI causes its
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nuclear foci to disperse to Rad5I foci. In this way, c-Abl association with BRCAI may indirectly
regulate DNA repair proteins.
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Figure 9 - BRCAI Pathway
Ultraviolet and Ionizing Radiation begin the BRCAI checkpoint and repair pathways. Gl and G2/M arrest
are dependent upon BRCAI disassociation from c-Abl and CtlP. Cyclin-dependent kinases are regulated by
upstream proteins p53, GADD4, and Chkl . Figure created using BioCarta Pathway templates and Pathway
Assist.
Compared to BRCAI little is known about the second gene, BRCA2, which lies on
chromosome 13 (Wooster, 1995). The gene's exact function has not been uncovered but its
interaction with RAD5I reveals it too participates in homologous recombination (Howlett, 2002).
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Following phosphorylation by ATR, BRCA2 may inhibit RadSI to control double-stranded repair
(Chen, 1999). In no way does BRCAI interact directly with BRCAI (Kato, 2000).
G2 repair
Homologous repair takes place in late S and early G2 phase when an undamaged sister
chromatid is available for use as a template. The NBS1 S-phase checkpoint response functions at
the intersection of two repair signaling pathways. The first pathway induces S-phase arrest while
the second promotes double-stranded break repairs (end joining) through FANCD2 (Wilda,
2000). Phosphorylation of NBS by ATR in response to ionizing radiation begins these repair
pathways (Figure 1 1 ).
Upon ionizing radiation the MRE11 complex assembles in nuclear foci with BRCAI
(D'
Andrea, 2003). ATR phosphorylates NBS1 in response to this ionizing radiation (Falck, 2002)
causing association with co-located MRE1 1-Rad50 (Figure 10). The complete NBS1-Rad50-
MRE11 (MRN) complex is a sensor of abnormal DNA structures and a regulator of post
replication repair process (Wang, 2002). Specifically, MRE1 1-RAD50-NBS1 acts as a double-
strand break sensor for ATM and recruits ATM to broken DNA molecules (Lee, 2005). BRCAI
mediates this reaction by acting as a Rad50 adaptor along exon 1 1 (Zhong, 1999). MRE11 then
regulates exonuclease resection of 5-prime double-strand ends and is involved in additional
checkpoint signaling (Huberman, 2005).
NBSl's second repair role is required for activation of the FANCD2 repair associated
protein (Pichierri, 1995). FANCD2 belongs to a group of nine proteins FA (Fanconi Anemia)
coupled with the BRCAI repair pathway. FA encoded proteins are essential for protection against
chromosome breakage detection (Garcia-Higuera, 2005). Though FANC encoded proteins share
little homology they cooperate in a serial pathway essential for regulating the G2-checkpoint and
DNA repair. Six of these proteins (A, C, E, F, G. and L) assemble in a nuclear complex that is
required for activation of FANCD2 (Garcia-Higuera, 2005).
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During S-phase FANCD2 is monoubiquitinated by ATR in response to IR and is targeted
to nuclear foci (dots). It is believed NBSl acts an adaptor for A77?-mediated phosphorylation of
FANCD2 (Pichierri, 1995). Once activated it assembles with BRCAI, BRCA2, NBSl and RadSl
in the perinuclear compartment of the endoplasmic reticulum (Coene, 1 997). Monoubiquitination
by BRCA1-BARDT is a G2 accumulation checkpoint response leading to genomic stability and
promotion of homologous recombination. Although ATM is not necessary for the FA pathway it
does increase the efficiency in IR conditions (Taniguchi, 2002).
IR S phase delay
FANCA
FANCC
FANCD2 FANCD2 P
(Z)
FANCF
FANCG
G2 accumulation Genomic Stability
Figure 10 - BRCA1-FANCD2 Pathway
ATR activation ofNBS1-MRE1 1-Rad50 complex regulates the post replication repair process at the S-phase
checkpoint. Simultaneously, interaction between BRCAI and FANC proteins stimulate nucleotide excision
repair to restore genetic stability. Figure created using BioCarta Pathway templates and Pathway Assist.
FANCA interaction occurs in the central region of BRCAI at aminos 740-1083. This
leads to FANCD2 phosphorylation and eventually the DNA replication fork restart (Folias, 2002).
The outcome of this response is either genomic stability or cellular genotoxicity (apoptosis) in
non-repairable conditions. In this region Lys820Glu and Gly960Asp are two frequent causing
cancer mutations though neither affects binding (Folias, 2002).
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Figure 11 - BRCA1-FANCD2 Pathway
This figure is a representation of the FANCD2 pathway from data correlated Pathway Assist. Pathway
Assist identifies protein and cell process relationships from PuhMed literature searches.
M phase
BRCAI acts in multiple pathways, checkpoints and effectors. The onset of mitosis is a
strictly controlled process dependent upon ATM, CHK and BRCAI among other proteins. The
replication fork restart is managed mostly by proteins associated with the BRCT repeats but also
controlled by FANCD2 and MRE11-Rad50.
Structure ofBRCAI Proteins
The BRCAI gene contains 24 exons (22 coding) spanning 81k base pairs encoding an
1863-residue multifunction protein. Exon 1 contains two alternative non-coding exons which are
duplicates of exon 1 and 3 of the adjacent NBR1 gene (Puget, 2002). Exon 4 is usually non-
coding unless an Alu mutation causes a premature stop codon. The other non-coding introns
range between 400bp-9kb in size. BRCAI contains three main binding regions, one at the (acidic)
carboxyl-terminal region (BRCT), another at the N-terminal (RING) and a vast central region.
The C-terminal domain, deemed BRCT, binds with several proteins involved in maintaining
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genomic integrity (Yarden, 2002). Protein-protein interactions are regulated by a zinc finger
located at the N-terminal side. Figure 12 shows the different binding regions of BRCAI .
N-terminus (RING) C-terminus(BRCT)
BARD1
P53
Rad50 Rad51
ATR ATM
BACH1
p53
CtlP
Figure 12 - BRCAI Binding Domains
BRCAI interacts with a magnitude of proteins across the entire 1853 amino acid protein. Key proteins p53,
BACH I. and CtlP compete for binding at the C-terminal domain.
BRCT - BRCAI C-terminal
BRCAI houses two tandem repeats of BRCT motifs at the C-terminal regions. BRCAI
belongs to a family of more than 23 BRCT motif-containing proteins (Callebaut, 1997). These
motifs are known to be involved in tumor suppression through DNA damage detection and repair
activities (Yu, Xin.). BRCT is a phosphoprotein binding domain meaning interactions occur in a
phosphorylated-dependent manner (Yu, 2003). The BRCT region interacts in a phosphorylation-
dependent manner with DNA damaged-induced proteins BACH1 & the transcriptional
corepressor CtlP peptide to control G2/M checkpointing.
BRCT is approximately 200 amino acids in length spanning codons 1646 to 1859 which
cover exons 16-24. Within this region are two tandem repeats each 95 amino acids long named
BRCT1 and BRCT2 (BRCT-N and BRCT-C, respectively). Each BRCT domain folds
independently before assembling into a quaternary structure (Gaiser, 2004). The tandem repeats
are necessary as each contains a single receptor site for a binding complex (Shiozaki, 2004).
Residues 1646-1740 fold into a 4-stranded parallel beta-sheet surrounded by 3 alpha-
helices forming a single domain. Each domain contains four beta-sheets flanked by two alpha-
helices on one face and a third on the opposite surface (Figure 13a) (Varma, 2005). An
asymmetric tertiary structure (dimer) is formed by the grouping of the two BRCT (BRCT1,
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BRCT2) domains in a head-to tail manor (Figure 13b). The genomic layout of each secondary
structure is n-fjlal32(33a2|34a3-c.
The hydrophobic surfaces of the domains create a channel/groove that is important to the
binding of CtlP and BACHI. The hydrophobic pocket is made of Argl699, Leu 1701, Phel704,
Asnl774, Metl775, Argl835, and Leul839 (Varma, 2005). The first surface is responsible for
attracting a phosphoserine residue while the second determines the protein recognition specificity
(Shiozaki, 2004).
BACH1 (fi/?G47-Associated C-terminal Helicase 1 ) is a DEAH helicase molecule
providing upstream regulation of double-strand break repair. BACHI (BRIP1) neighbors BRCAI
mapping at 17q22. It contains 20 exons encoding 1249 amino acids. Each dimer interface
contains a single receptor site for BACH! (Shiozaki, 2004). BACH1 introduces itself at the
junction of the two BRCT domains binding with its own Ser990 and Phe993. These amino acids
are heavily responsible for BRCAI binding and require phosphorylation at Ser990 to be
recognized (Shiozaki, 2004). BACH1 pSer990 binds via hydrogen bonding to backbone Glyl656
and side chains of Serl 655 and Lysl702 on the first BRCT repeat. An additional single hydrogen
bond between Ser998 and Glyl656 forms for stability.
BACHI Phe993 at the C-terminus binds in the hydrophobic cleft formed at BRCT
backbone atoms Thrl700 and Leu 170 1 primarily through van der Waals forces. Phe993 is
anchored to sidechain molecules Phel704, Asnl744, Met 1775, and Leu 1839. The vein of the
pocket is formed by the latter three amino acids found on the second BRCT repeat. Additional
salt bridges and hydrogen bonds stabilize the molecule (Shiozaki, 2004).
Similar to BRCAI -BACHI, CtlP binds using phospho-Ser327 and Phe330 at the same
conserved cleft. The same major binding points Serl 655, Lysl702, Glyl656 and Leu 1701 are
utilized, though, several stabilizing bonds are missing from BRCAl-CtIP complex (Varma, 2005).
Phosphorylation of CtlP at Ser327 during G2 phase controls G2/M transition during brief
interactions with BRCT repeats.
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Figure 13 - Single BRCT Domain and BRCT Dimer
(a) Structure of a single BRCT repeat ( 1 JNX_A). Four parallel beta sheets are bordered by two alpha
helices and a third on distal side.
(b) BRCT tandem repeat bound in head-tail fashion. Dark green and light blue helices form backbone of
hydrophobic pocket for CtlP and BACHI binding.
Visualization created using Molscript from PDB entry IJNX.
RING - BRCAI N-terminal
At the N-terminus BRCAI region lays a RING finger domain mediating protein-protein
interactions. The RING domain confers E3 ubiquitin (Ub) ligase activity leading to genomic
stability (Chen, 2002). In the BRCAI pathway BARD1 (BRCA-associated RING domain 1)
enhances ubiquitin enzyme activity and the ability of DNA binding (Brzovic. 2001).
The RING protein is approximately 100 amino acids in length extending from amino 1
through 103 covering exons 2-7. The tertiary structure consists of three alpha helices, three beta
sheets and two Zinc binding loops (Brzovic, 2001). Residues 8-22 and 81-96 form anti-parallel
alpha helices flanking the central backbone at 23-76. A third helix from residues 46-53 is
separated from the backbone by three near parallel beta sheets. The very short beta sheets
originate from residues 35-37, 42-44, 74-76.
The RING tertiary structure is very unique consisting of three cysteine residues, one
histidine, and another four cysteines in a doubled-over ring pattern often referred to as a 'cross-
brace'
motif. In the middle of each ring binds a Zinc atom (Figure 14). The RING motif consists
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of seven Cysteine residues and Histdine residues arranged in pairs spaced two amino acids apart
(Brzovic, 2001). This is also known as a C3HC4-type ring variant (Figure 14). Two binding
domains are formed by these residues which interact with two
Zn2+
atoms. Site I is formed by
residues Cys 24, Cys 27, Cys 44 and Cys 47. Site II ligands include Cys 39, His 41, Cys 61 and
Cys 64. These sites differ greatly from BRCT in that there is significant overlap between
contributing amino sequences.
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Figure 14 - C3HC4 Representation
A representation of the Zinc ring finger found at the N-terminus of BRCAI . Two overlapping loops form
the unique 3Cysteine-Histidine-4Cysteine (C3HC4) patterned cross-brace motif attracting Zinc ions.
The portion of BARD1 with binding affinity to BRCAl's RING contains a similar RING
domain. BARD1 exhibits homology to BRCAl's RINGs with a slight alignment shift and five
fewer amino acids. BARDI residues 36-48, 101-116 form the same alpha helices surrounding the
central motif at 49-100. Residues 61-63 and 69-71 form two beta sheets. Notice BARDI is
missing both a beta sheet and the diminished lower alpha helix.
Zn2+
site I is shifted toward the
3'
end to Cys 50, Cys 53, Cys 71 and Cys 74 and respectively site II to Cys 66, His 68, Cys 83
andCys86inBA/tD/.
In the BRCAI -BARD I heterodimer complex the BARDI subunit's two alpha helices
bundle with the BRCATs. In Ubiquitin ligase (E3) complex primary interaction occurs through
the first Zn2+ loop, central helix, and second Zn2+ loop (Brzovic, 2001 ), essentially at the RING-
RING interface. The resulting dimer interface contains hydrophobic interaction points for
binding to other proteins. Helix side chain residues Gin 19, Leu22, Val83, Glu84, and Leu87
contact Leu30, Ile31 and Lys32 in the subunit (Brzovic, 2001). The helix angle between fingers
is determined by these residues forming a cleft for E3 ligases UbcH7 and UbcH5 binding. The
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BRCAI -BARD interface occurs though helical side chain interactions at Arg7, GlulO, Glu85, and
Asp96 (Figure 15).
Figure 15 - BRCAI RING Domain bound to BARDI
Two alpha helices compose the backbone binding region of the BRCA 1 RING domain pictured in blue and
green. The dark green lower portion denotes the Zn-finger responsible for E3 ubiquitin-ligase activity. On
the left in brown is the homologous BARDI protein forming a complete heterodimer. Visualization created
using Molscript from PDB entry 1JM7.
Other BRCAI Binding Sites
Although the BRCT and RING domains account for only 16% of the BRCAI gene, the
remaining structure remains largely unstudied. Several other important binding sites occur in the
central region though it is generally less structured than the terminal ends.
FANC complex protein FANCA interacts in the BRCAI central region at residues 740-
1083 (Folias, 2002). FANCC may also interact in this region to up-regulate FANCD2 but the
binding sites are unidentified.
Amino acids 340-534 exhibit beta sheeting folding in a flexible manor possibly allowing
binding to several different conformations. Experiments suggest this region is involved in
homologous repair through binding to four-junction DNA (Naseem, 2006). However, no protein
binding sites were identified in this region.
38
In response to DNA damage, Cdsl (Chkl) regulates BRCAI through phosphorylation of
Ser998 (Lee, 2002). Phosphorylation at this site is required for release from hCds2 molecule to
restore S-phase and M-phase.
In response to IR, ATM phosphorylates at Serl387 for intra-S checkpoint (Gatei, 2001).
During G2/M checkpoint ATM phosphorylates at Serl423 and Serl 524 in response to both IR and
UV (Choudhury, 2005). It appears ATM phosphorylation of BRCAI Serl423 at these Serines act
as a p53 adaptor allowing ATM phosphorylation (Fabbro, 2004). Mutations at any of these sites
will likely affect BRCAI binding affinity and function.
BRCAI Mutations
Various mutations are introduced into all DNA during replication, transcription, and
translation. These may be as simple as a single nucleotide substitution, insertion or deletion
(indel), or as complex as inversions, breaks, splices, and rearrangements. In 1994 Swensen found
an 1 1-bp deletion and a 1-bp insertion creating a stop codon in exon 2 leading to initial isolation
of the BRCAI gene (Miki, 1994). Since then, the NIH Breast Cancer Mutation Database has
documented more than ten thousand other mutations.
Each exon encodes between 37-300 base pairs with the exception of exon 1 1 which
covers over 60% of the gene. Mutations are evenly distributed through coding regions though
due to its size exon 1 1 contains the majority. About 70% are insertion frameshifts, creating
truncated reading frames through a down sequence stop codon resulting in severely truncated
protein products approximately 85% of the time. The top three reported mutations represent 30%
of the total and fall into one of the terminal regions. About one-third of mutations in either
terminal domain are of missense type.
Most Frequent Mutations Reported by BIC
Using the Breast Cancer Information Core Database (BIC) database the most frequently
occurring exon mutations are 185delAG, 5382insC, C61G, R1347G, R841W. The first two
produce premature stop codons in the BRNT and BRCT regions. The C61G mutation falls into
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third exon of RING domain severely affecting confomation, resulting in the inability to confer
ubiquitin ligase (E3) activity (Mallery, 2002). The other two mutations both are missense
mutations in exon 1 1 with no known effects.
BRCT Mutations
The BRCT region spans exons 16-24 covering codons 1646-1859 and is a frequent
location of cancer causing mutations (Table 7). 5382insC is the most frequent mutation occurring
within this range. As the designation implies, it is an insertion mutation at codon 1756 (cDNA
position 5382) resulting in a frameshift stop codon at 1829. Every frameshift mutation in this
domain results in a premature stop codon within the coding region. Additionally, some single
nucleotide polymorphisms (nonsense mutations) at Argl835 and Argl751 cause stop mutations.
All of these stops result in truncation of one or both BRCT repeats and ultimately inactivation of
the protein. Truncation of only one repeat does not allow protein binding since no hydrophobic
pocket is formed. Lab experiments show BRCT can withstand small truncations but deletions
greater than 8 residues hinder protein folding (Williams, 2003).
A mutation introduced at intron 21 (VIS21-36del510) results in a down-sequence stop
codon at the 1805 amino acid (Williams, 2003). Other mutations in this region such as R1751Q
disrupt salt bridges in the BRCT linker helix (Williams, 2003). Larger deletions such as the
removal of exon 21 or 22 remove enough of the functional domain to inhibit any protein folding
or bonding (Zikan, 2005).
The frequently occurring missense mutations Met 1652, Argl699, Ala 1708 and Met 1775
occur on the BRCT repeats (Cantor, 2001 ). Met 1775 and Argl699 reside on opposite domains in
the conserved surface cleft. BACHI Phe993 stacks closely against the second repeat at sidechains
of Met 1775. Mutation M1775R is unlikely to alter folding but does result in a charge-charge
repulsion at the hydrophobic core (Williams, 2001). This significantly disrupts recognition of
BACHI and CtlP (Vallon-Christersson, 2001 ). In CtlP, the substitution change causes Phe330 to
collide with the sidechain of Argl775 (Varma, 2005). Lab experimentation has shown double-
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strand break repair is abrogated by mutation at this site (Figge, 2004). Substitutions at A 1708,
M1775 and M1783 are considered interface mutations whereas protease sensitivity falls and
hydrophobic core disruption results from these changes.
Table 7 - Frequent BRCAI Mutations
The most frequently occurring mutations according to the Breast Cancer Information C
are listed in this table. Although mutations are evenly distributed throughout all exons
mutations 185delAG, 5283insC and C61G account for approximately 30%.
ore Database (BIC)
the top three
Exon Designation Type NT Codon Effect Count
2 185delAG F 185 23 Stop 39 1596
20 5382insC F 5382 1756 Stop 1 829 836
5 C61G M 300 61 M 155
11 R 1 347G M 4158 1347 UV 149
1 1 R841W M 2640 841 UV 114
11 Ml 0081 M 3143 1008 UV 105
1 1 4184del4 F 4184 1 355 F 105
13 R1443X N 4446 1443 N 103
11 3875del4 F 3875 1252 F 97
11 E1250X N 3867 1250 N 76
11 Q563X N 1806 563 N 70
16 M 1 628T M 5002 1628 UV 70 J
18 A1708E M 5242 1708 M 39
Argl699 participates in salt bridges between the BRCT repeats and shared hydrogen side
chains of Phe993. R1699W affects tertiary structure stability which significantly disrupts BACHI
and CtlP bonding (Vallon-Christersson, 2001). R1699Q has no effect and R1699S disrupts the
salt bridge interface (Vallon-Christersson, 2001). Modeling of the transition from Arginine to
Tryptophan predicts Trpl699 sterically collides with Phe330 obstructing entrance to the
hydrophobic pocket (Varma, 2005). Inhibition at this site undoubtedly disrupts double-strand
break repair (Scully, 1999).
The two other common missense mutations occur at Met 1652 and Ala 1708 and are
buried deep in the hydrophobic crevice. A1708E is on the first domain and Met 1652 is on the
second. The A1708E mutation is the most frequently occurring BRCT repeat mutation according
to BIC. Alteration at these points disrupts folding, and ultimately the final protein structure
(Shiozaki, 2004). A positively charged Alanine to a negatively charged Glutamine destabilizes
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structure producing an insoluble domain. This is a clear example of tertiary structure relating to
function.
Ml 6521 is thought to be a benign polymorphism due to its peripheral location on the C-
terminus of the first BRCT repeat. Although found frequently in the presence of cancer-causing
mutations it has not been shown to cause structural deformities (Williams, 2003). D1692N is a
common mutation in cancer patients but a direct link to cancer has not been established. This
mutation causes a weakening of the salt bridge to S1715 but does not significantly affect the
conformation.
BACHI binds to the backbone molecules Glyl656, Serl 655 and Lysl702. Serl 655 and
Lysl702 sidechains donate hydrogens to BACHI Ser990 while Gly 1656 has an additional binding
to backbone BACHI pSer998. Serl 655 has several frequently occurring 19 base frame shifts
resulting in an upstream stop codon at 1670. This renders a shortened non-functioning protein.
Missense S1655F mutation completely blocks interaction with BACHI pSer990 (Shiozaki, 2004)
and CtlP Ser327 (Varma, 2005). Though very disruptive the BIC database only reports a single
occurrence at Gly 1656 and Lysl702.
Atoms in the backbone of the pocket such as Thrl700 and Leu 1701 show only a few
frameshift mutations. Changes (other than deletions) at these sites would weaken BACHI
binding by diminishing van der Waals contacts at Phe993.
Remaining backbone binding sites Phel704 in the first repeat and Asnl774 and Leul839
in the second have no mutations listed in BIC. To analyze mutations at Phel704, Asnl774,
Leu 1839 residues, I mutated amino acids at each site to the most common amino change. For
example, Phenylalanine most frequently mutates to Leucine in BRCAI. Therefore, in my
predicted structure, Phenylalanine was changed to Leucine. Similarly, Asnl774 was mutated to
complementary Lysine and Valine and Leu 1839 was mutated to Valine and Phenylalanine.
F1704L had no significant changes in between the base and predicted models other than a
7 degree Phi change, although it is possible this change would obstruct the BRCT cleft for CtlP
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or BACHI. The mutated A1774K/V angles lie in forbidden regions of the Ramachandran for
both the stock and predicted models. ProteinPredict shows a three-fold increase in relative
solvent accessibility for the Lysine mutations. No significant change is seen for modification to
Histidine. Based on these results mutations are unlikely to interfere with binding activity though
crystallography analysis would be necessary to confirm these results.
Table 8 - BRCT Secondary Structure Effects
Mutations have a wide variety of effects on secondary structures ranging from little or no effect to
completely abrogating binding ability. Note mutations at Arginine 1699 (R1699) have different effects
depending upon amino acid modification.
Mutation Structure Location Predicted Structure Changes Citation
M 1 65 1 1 N-b3 surface No effect (Williams, 2003)
Ml 6521 N-b4 surface No effect (Deffenbaugh, 2002)
D1692N N-G3/a2 Destabilizes salt bridge with S1715 (Joo, 2002)
D1692Y N-surface Slightly alter protease recognition (Joo, 2002)
Q1694X Skip exon 18 (Liu, 2001)
F1695L N-surface No effect (Joo, 2002)
V1696L N-surface Slightly alter protease recognition (Joo, 2002)
C1697R N-surface Alter folding & strong destabilizing (Williams, 2003)
R1699W N-a2 surface Affects stability (Worley, 2002)
R1699Q N-a2 surface None (Hayes. 2000)
R1699S N-a2 surface Disrupts interface salt bridge (W lliams. 2003)
F1704L N-a2 core No significant change (W Uiams, 2003)
A1708E N-a2 surface Dirupts interface / hydrophobicity (W lliams. 2003)
S1715R N-b4/a3 fold Alter folding & strong destabilizing (W lliams. 2003)
W1718C N-a3 fold Alter folding & strong destabilizing (W lliams, 2003)
T1720A N-a3 surface No effect (W lliams. 2003)
G1738R NIC interval Alter folding & strong destabilizing (W lliams, 2003)
G1738E N/C interval Alter folding & strong destabilizing (W lliams. 2003)
P1749R C-b3 surface Alter folding & strong destabilizing (W lliams, 2003)
R1751Q C-al surface Salt Bridge disruption (W lliams, 2003)
A1752P C-b3 surface Disrupts helix linker (W lliams, 2003)
I1766S C-b3 fold Alter folding & strong destabilizing (W lliams. 2003)
N 1774V C-terminus surface No significant change (W lliams, 2003)
M1775R C-a2 surface Dirupts interface / hydrophobicity (W lliams, 2003)
M1783T C-a2 surface Dirupts interface / hydrophobicity (W lliams, 2003)
G1788V C-surface Alter folding & strong destabilizing (W lliams, 2003)
G1788V C-surface Disrupts al-b2 turn (W lliams, 2003)
V 1 804D C-b3 surface No effect (W lliams, 2003)
V1809F C-b3 surface Alter folding & strong destabilizing (W lliams, 2003)
V1833M C-b4 pocket Alter folding, destabilize hydrophobic pocket (W lliams, 2003)
W1837G C-a3 core Alter folding & strong destabilizing (W lliams. 2003)
W1837R C-a3 core Alter folding & strong destabilizing (W lliams, 2003)
LI 839V C-a3 surface Alter folding & mild destabilizing (W lliams. 2003)
Y1853C C-terminus surface Alter folding & strong destabilizing (Williams. 2003)
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If present in vivo, the LI 839V mutation would fall within a conserved surface cleft
region. This is an area of highly conserved residues. Helix prediction decreases significantly for
the L1839V mutation. Coupled with Psi/Phi angle changes the a3 helical conformation is
significantly changed.
Table 8 lists secondary structure effects caused by SNPs or amino acid mutations. Most
of these amino acids occur on the surface of alpha helixes or beta sheets. Although some
mutations present little or no effect, the majority alter folding and are highly destabilizing to the
protein structure.
RING Mutations
The N-terminal region of BRCAI contains a zinc ringer finger domain covering 103
residues over a five exon span. Approximately 15% of BRCAI mutations are found within this
short range including the most common, 185delAG, occurring 1600 times. The adjacent
188dell 1 mutation lead to Miki's discovery of BRCAI in conjunction with C61G and C64G.
Similar to BRCT, some mutations at critical binding sites affect conformation while
others have little structural effect. For example, the frameshift of two amino acids at Glu 1 85
generate an early Stop codon rendering the protein unviable and truncation of the all but the first
alpha helix. This is unlike the more common R71G substitution falling adjacent to a beta sheet
but having little effect on final conformation.
According to BIC data, site II mutations occur ten times more frequently than in site I.
Lab experiments have shown mutations at residues Cys39, Cys61 and Cys64 in the second loop
still allow for binding with BARDI (Brzovic, 2001). Though occurring more frequently site II
mutations are far less disruptive to BRCAI function. This is supported by the fact that site I
ligands are targeted as predisposing patients with cancer. Site I missense mutations at Cys24,
Cys44, or Cys47 cause improper protein folding and ultimately abrogate Ub-ligase ability to
confer (Brzovic, 2003). Mutations at Site II Cys27, His41 have not been seen in patients.
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Only a handful of mutations were reported in the helix and Ub-cleft regions. Ub-cleft
mutations significantly alter the width of the binding interface and hinder Ub activity. At the
dimer interface mutations alter the protein's affinity toward BARD. It is unknown at this time the
exact impact if the charge field is tolerated.
In an attempt to predict mutation effect at Cys27 and His41, I passed two mutated 1JM7
sequences through ProteinPredict and SwissModel. I modified these residues to Tyrosine as it's a
commonly mutation in the Zn2+ rings. Secondary structure prediction was done using
ProteinPredict, SwissModel and DeepView. C27Y and H41Y modifications were submitted to
all prediction schemes at Protein Predict. C27Y had mixed predictions for helix and sheet content
but almost 90% confidence for non-secondary structure regions. PROFsec (secondary structure)
search results show an intact helix at residues 27-30 but with ultra low prediction reliability. This
is confirmed by PROFacc (accession) prediction for no secondary structure with a medium
confidence between 33-55%. Relative solvent accessibility falls in the 9% range which compares
favorably to the stock germ sequence.
H41Y differed slightly with PROFsec predicting helix, strand, or neither equally
plausible with 40% confidence. PROFacc predicted moderate solvent accessibility within the
H41 region which is consistent with the residue location at edge of beta sheet 2. ProteinPredict
predicted a high confidence both mutations would remain as strands with 0-9% solvency.
The modified sequences were then fed into SwissModel to generate predicted PDB files.
The predicted files were then rendered in MolScript and also viewed in DeepView for accessing
the quality of the structure.
Using DeepView to analyze the secondary structure, both Psi and Phi angles increased
about 5 degrees between the original model and a single mutation. Neither the H41 nor C27
mutations have values resulting in sterical clashes. Limited structure variability exists compared
to the unmanipulated protein sequences so binding would probably continue with Zn2+.
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Table 9 lists other mutation sites within BRCAI -N. Less structural research on N-
terminal mutations has been conducted than on the C-terminus. BARDI structural mutation
research far exceeds that done on BRCAI N-terminus. As can be seen in the table C39, C44, and
C47 modifications alter folding but with unknown consequences. Perhaps the most significant
mutation is the Leu53 and Leu53 in alpha helix-2 that abolishes bonding with BARDI.
Table 9 - BRCN Secondary Structure Effects
There are two areas of importance for mutations in the N-terminal region. First, mutations found along the
backbone structure affect the ability of BARDI to bind efficiently. Second, mutations in the RING will
influence Ub-ligase activity.
Mutation Structure Location Predicted Structure Changes Citation
R7C Adjacent to al Destroy salt bridge w/BARDl Trp34 (Brzovic 2001
C24R Adjacent to al Alter folding (Brzovic 2001
C27 Central motif No effect predicted
H41 Central motif No effect predicted
C44F b2 surface Alter folding (Brzovic 2001
C47F Adjacent to a2 Alter folding (Brzovic, 2001
C39S Between bl-b2 Slight structure alteration (Brzovic, 2001
C39R Between bl-b2 Slight structure alteration (Brzovic, 2001
C39Y Between bl-b2 Slight structure alteration (Brzovic, 2001
L52F a2 surface Protein-protein interaction (Brzovic, 2001
L53F a2 surface Protein-protein interaction (Brzovic, 2001
C61G Central motif Unknown
C64G Central motif Slight structure alteration (Brzovic. 2001
C64Y Central motif Slight structure alteration (Brzovic, 2001
R71G Adjacent to b3 No effect
Central Region / Other Domain mutations
Other regions in the BRCAI gene have important functions but neither well defined
domains nor binding sites. Unfortunately this inhibits research on structural changes caused by
mutations in the central domain.
Exon 11 encodes approximately 61% of the gene by spanning codons 263 to 1370.
Deletion of this exon renders a truncated nonfunctioning p53 binding site. p53 mediates
transcription in BRCAI ranges 224-500 and the second BRCT domain but exact binding sites are
unknown (Zhang, 1998).
46
Only one mutation at Serl423 is listed in BIC for all the binding sites. Mutation at
Serl423 abrogates ATM ability to phosphorylate this site (Xu, 2001). However throughout the
1241-1530 range over one-thousand mutations are listed mostly consisting of Ser to Ser
polymorphisms or Arg to Stop changes.
Cdsl (hCdsl/Chkl) binds at Ser988 to regulate BRCAI through phosphorylation. In-
vitro mutations at this residue have been shown to abrogate the ability of Chkl to regulate BRCAI
(Lee, 2002). Mutation at Ser988 abrogates ability of Chk2 to phosphorylate BRCAI and restore
cell cycle after DNA damage (Liu, 2002). Qin reported Chk2 may also bind to Thrl852 in the
BRCT region (Qin, 2003). No mutations have been reported to BIC at either site or additional
data to support his findings.
CDK2 (Cyclin-dependent kinase E) phosphorylates BRCAI at Serl497 and Thr967.
Substitution of Serine to Alanine or Threonine to Asparagine lowers but does not prevent CDK2
phosphorylation along this region (Ruffner, 1999).
Table 10 - BRCAI Central Region Mutations
Few mutations are documented in the central region of BRCAI . Laboratory testing has demonstrated
mutations at key binding sites severely inhibit binding.
Mutation Structure Location Predicted Structure Changes Citation
Thr967 Exon 1 1 May effect CDK2 phosphorylation. (Ruffner, 1999)
Ser988x Exon 1 1 May effect Chk2 binding. (Liu, 2001)
del Exonl 1 Exon 1 1 p53 unable to bind to BRCAI. (Zhang, 1998)
Ser 1423 Exon 13 Abrogates ATM ability to phosphorylate. (Xu. 1999)
Serl497x Exon 14 May effect CDK2 phosphorylation. (Ruffner, 1999)
Thrl852x Exon 24 None (Qin, 2003)
BRCAI Conservation
To study gene conservation I first observed conservation at the known binding points
located at each terminus. I then searched for homologous sequences around central region
phosphorylation sites. Finally, I compared conservation at the terminals to other species.
Starting with the RING section of BRCAI a FASTA formatted sequence of 1JM7 was
submitted to NCBI's PSI-BLAST (Table 1 1 ).
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The majority of BLAST results were laboratory isoform splice variants. These results
were discarded from the homology search because they do not naturally occur in vivo.
__________
IJM7 is the solution structure representation of BRCAI -BARD I RING-domain heterodimer. The amino
acid sequence for BRCAI (Chain_A) is listed below from NCBI Gl: 15988069.
MDLSALRVEEVQNVINAMQKILECPICLELIKEPVSTKCDHIFCKFCMLKLLNQKK
GPSQCPLCKNDITKRSLQESTRFSQ-VEE-LKIICAFQ-DTGLEYANSYNFAKKGK
Additional searches were conducted using NCBI-Blast2, RPS-BLAST, and CDART to
gather sequences from alternative Uniprot and SwissProt databases. Sequences from all search
results were combined into a single text file for multiple alignment in ClustalW. Several other
alignments using PHD and MaxHom (Multiple Sequence Alignment) from Protein Predict did not
yield significant complements.
Table 12 - Conservation of RING Domain
1 JM7 RING domain aligned against other Human sequences. Little homology exists throughout N-
terminal region, however, note exceptionally strong conservation ofC3HC4 RING (blue) amino acids.
Alpha helices are denoted in red. Beta sheets in yellow. Sequences are labeled with protein and NCBI Gl
number.
1JM7 | 15988069: 8
TRIP31 | 55961262 : 1
Tri3l| 1770499: 16
RNF1 | 11022690: 1
INF1|Q9BYJ4: 1
TRIM22 | 23272543 : 1
TRIP22|Q8IYM9: 1
TRIP5 |Q9C035 : 1
Ro/SSA|14790039: 1
SSA1 | 14994115: 1
SjAl|53690156: 1
SSA56 | 15982946: 1
RING137 | 80474981:1
IRIS|37537746: 7
Breast | 94315232: 7
LON1 | 73747840 : 15
Neuro| 68032982: 15
Tri73 |Q86UV7: 1
RAD18 |Q9NS91: 9
HSD4 | 6468773: 2
TRAC1 |Q96EQ8: 15
TNF6IQ9Y4K3: 15
| 10 | 20 | 30 | 40 | 50 | SO
veevqnvinamqkile|piIlelikepvst-kcdhifckfcmlk-llnqkkgpsq|plBkndit
-MASGQFVNKLQEEVl|piiLDILQKPVTI-DiG|NFlLKllTO-IGETSCGFFKgPLBKTSVR
-^4ASGQFVNKLQEEVIlpIlLDILQKPVTI-DlGfINFCPQCITQ-IGETSCGFFKlpLIKTSVR
-MASKILLN-VQEEVTBPllLELLTEPLSL-DSGfeSLCRAGITVSNKE-MGGKSS|PvfiGISYS
-maskilln-vqeevtIpiIlellteplsl-dIg^slpracitvsnke-mggkssBpvBgisys
-mdfsvkvd-iekevt|pi|lellteplsl-dIghsfCqacitakike-srgess|pvSqtrfq
-mdfsvkvd-iekevtBpiBlellteplsl-dBg&sfcqacitakike-srgessBpvBqtrfq
-masgilw-vkeevtcpiclelltqplsl-dcgh'sfcqacltanhkk-dkgesscpvcrisyq
-masaarltmmweevt|pi|ldpfvepvsi
-eIgWsfcqeCjIsqvgkg--
-ggsvBpvBrqrfl
-masaarltmmweevtIpiIldpfvepvsi
-eIgbsfcqecisqvgkg-- -ggsvBp Brqrfl
-masaarltmtweevtIpiBldpfvepvsi-eBgIsfcqecisqvgkg-- -ggsvBpvBrqrfl
-mdptalveaiveevadpiomtflrepmsi-di2ghsfchsclsglwei-qnwgytcplcrapvq
lveaiveevacpicjmtflrepmsi -dc'ghsfchsclsglwei -qnwgytcplcrapvq
VEEVQNVINAMQKILEipi|LELIKEPVST-KlD|lFpKFdMLKLLN-QKKGPSQ|pL|KNDIT
VEEVQNVINAMQKILECPICLELIKEPVST-KCPHiFCKFCMLKLLN-QKKGPSO'CPLCKNDIT
GAAAAAAATEVWDGFKCRKCHGFLSDPVSL-SBGHTFCKLCLERGRAADRRCALCGVKLSALMV
EGGPAPEPRAPRDLLGCPRCRRLLHKPVTL - P|GLTV|KRjVE PGPAR PQVRR
-MAWQVSLLELEDRLQfjPI^LEVFKESLML-QCGHSYCKGCLVSLSYH-LDTKVRCPMCWQVVD
WPPGLAVMKTIDDLLRCGICFEYFNIAMIIPQCSH'NYCSLCIRKFLSY KTQCPTCCVTVT
AEDLSAATSYTEDDFYCPVCQEVLKTPVRTTACQHVFCRKCFLTAMRE- -
-SGAHCPLClRGNVT
ALERRRDPELPVTSFDqAVqLEVLHQPVRT-RCGHVFCRSC:IATSLKN---NKWTC;PYCRAYLP
QGYDVEFDPPLESKYEqPiq:LMALREAVQT-PCGH;RFCKACIIKSIRD---AGHKqPVDNEILL
Reviewing the multiple alignments yielded some interesting results. The 1JM7 alignment
is nearly identical within the two ring regions in most other sequences. Sequences in Table 12 are
listed in descending order of homology score (E-value).
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While all the sequences exhibit strong sequence similarity to the first RING Cysteines
and Histidine, the second RING is less similar. TR/P3I and TRI31 RINGs exhibit strong
homology at both binding sites and the surrounding RING region.
RNF21 (Long Interferon-responsive finger protein 11) clone and INF1 (Interferon-
responsive finger protein 1 ) are interferon-responsive finger proteins. Both are highly conserved
at binding points including the Histidine. This high level of conservation may be attributed to the
double RING box-coiled coils (RBCC) shape. This unique structure does not tolerate many
mutations. TRIP5 (Tripartite motif-containing protein 5) and TRIM22 / TRIP22 (Tripartite motif-
containing 22) also express similar homology. The remaining sequences vary greatly and express
little homology outside the key binding sites.
The BRCT repeats interact with phosphorylated proteins containing the signature
sequence pSer-X-X-Phe where X indicates any residue (Varma, 2005). Threonine and
Tryptophan terminated sequences are also possible but research suggests this combination is
(Varma, 2005). This unique configuration allows numerous mutations between the Phe and Ser
binding points to have minimal or little effect on BRCT recognizing BACHI .
Table 13 - 1JNX
1JNX is the crystal structure of the BRCAI C-terminal repeat from NCBI Gl: 15988247.
VNKRMSMWSGLTPEEFMLVYKFARKHHITLTNLITEETTHWMKTDAEFVCER
TLKYFLGIAGGKWWSYFWVTQSIKERKMLNEHDFEVRGDWNGRNHQGPKRAR
ESQDRKIFRGLEICCYGPFTNMPTDQLEWMVQLCGASWKELSSFTLGTGVHPI
VWQPDAWTEDNGFHAIGQMCEAPWTREWVLDSVALYQCQELDTYLIPQIP
Entrez Protein and PSI-BLAST returned a combined total of 300 reference sequences for
Homo sapiens. Of these, only 17 are unique sequences and not isoforms. Far fewer alignments
were found at the ring domain. Using ClustalW the list was narrowed to 13 sequences containing
at least one conserved amino acid. I also attempted to BLAST a single BRCT repeat which
shortened the search sequence to just 96 amino acids. The results from this search were identical
to the full length search. My hypothesis had been a single BRCT domain would occur more
frequently than the dimer. This means no sequences are homologous to a single BRCT repeat.
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Several BRCAI related proteins show strong homology at the key binding sites for
BACHI and CtlP Ser998 and pSer990 (1655-56, 1702) and Phe993( 1699-1704, 1774-75, 1839).
It is interesting that the RING binding proteins BARDI and MDC1 (DNA Damage Mediator)
exhibit such strong identity to the C-terminus sequence. TP53 (p53 binding protein) has
somewhat less resemblance to the backbone chain yet maintains major binding sites.
G2/M phase regulators are the highly conserved because they control mitosis (Jin, 2000).
Residues interacting with the first motif (pSer990) are highly conserved while the second motif is
least conserved. Specifically, Phe993 binds at the hydrophobic pocket of 1774-1775 in exon 22.
In this region neither of these residues are preserved in MDCI, BARDI, or p53 being replaced by
different amino acids (Shiozaki, 2004). Exon 22 is the least conserved exon in BRCT.
Table 14 - Conservation of BRCT Domain
The C-terminal domain contains little homology at key binding sites and secondary structure. Blue denotes
homologous sites; Alpha helices in red; Beta sheets in yellow. Sequences are labeled with protein and
NCBI Gl number.
1JNX| 15988247
MDCI j 84040269
BARDI | 4557349
| 1655 | 1699 11774 | 1788 | 1839
165 3 WSGLPEML ElTLKYFLGIAG FTISIMPITDQIjEWM QLCGASWKjELS PWTREWVIiDS-
517 mdIpphqkqpqr rrtvkflcalgr vqppepqmgeii sccggtylpsmp jeflltgvlkqe
571 igsglsseqqkm qstlkcmlgiln fkhhrkdnlikl tagggqilsrkp cnyhpervirqgk
bardloc | 2828068 : rpvdytddesmk qstlkcmlgiln ekhhpkdnlikl tagggqilsrkp cnyhpervirqgk
TP53B | 8928568 : 1691 KPGAVGAGEFiVS CRTRKYFLGLAJS QQQNFLELMSEI MTGG4aSVKQHH PWSQEWVIQCL
TP53B | 488592: 745 KPGAVGAGEHVS CRT'RKYFLCLAiS QQQNFLELWSEI MTGGAASVKQHH PWSQEWVIQCL
MCPH1 |47605903 597 EEKENLPGGYSG Lffl^NVLLGIAR ASSPPVAKLCEL HLCEG KYLSEKWVLDS-
KIAA0259 | 1665785: HD|EIAKQAVCD LBNESLASVAA ILHVDQSREAGF LQSgGAKVLPGH YCLRTEYIADYL
CAGF28 | 2565046 : 8 KQNEVANVQPSS Tg^MFLAAISV GICPSLSTMKAI ECAIGKVLSKQP LHLCREYFARGI
XRCC1 | 139820: 131 VC|QPYSKDSPF EDE|RRVAEQKE FABTPKYSQVLG AGPfSSSEEDEA PVLQEDIDIEGV
SerFCPla | 3769521: QAQECGHLHWN iSGARGPPAPS LGEGSDDSDSEK RPEEQEEEPQPR EDAASESSRESS
VPARP|5702306
t-DONT| 181649
PESC|21542165
HPGGFTTRPSAG SHCPVFAFQSSD LNLNTNGLHSFL QKGIQSLGVKGR EDAASESSRESS
MTGGFRRGKKMG ESSFEKLRLPSR WTGSPRQFERDL R KAESEEEIFAHL
378 VDRPGQQTSVIG EKEGDYVPPEKL --EQRMEGKKPR MAGTLKLEDKQR IREANKLAEKRK
I was surprised the XRCC1 BLAST alignment has little sequence similarity to BRCT
other than a few key binding sites. Since BRCT style repeats in XRCCI were used as a
crystallography model for BRCAI, the aforementioned originally led me to anticipate a stronger
protein sequence homology.
To model BRCT, I used the XRCCI DNA repair protein, 1CDZ. Structure of an XRCCI
BRCT domain: protein-protein interaction module (Zhang, 1996) by Xi Zhang discusses the
sequence and structural similarities between these two repair proteins. They confer at high levels
of similarity, invariance and conservation. However, my own analysis shows few amino acids
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are actually conserved let alone ones forming important secondary structures or binding sites.
Only eight residues in all beta sheets and alpha helices are conserved (Table 15).
Table 15 - BRCT vs. XRCCI
The crystal structure ofXRCCI is often used to model BRCAl's tandem repeat. Little homology exists
between the two sequences though tertiary structure is remarkable similar. The 1JNX sequence is repeated
to clarify homologous sites (gray). Alpha helices are shown in red; Beta sheets in yellow. Sequences are
labeled with protein and NCBI Gl number.
|1730 | 1750 |1760 | 1770 | 1780
1JNX | 15988247 VRGDWNGRNHQGP KRARESQDRKIFRGLEICCYGPFTNMPTDQLEWMVQLCG-
1JNX | 15988247 VRGDWNGRNHQGP KRARESQDRKIFRGLEICCYGPFTNMPTDQLEWMVQLCG-
XRCC1 | 9954649 IEGVQSEGQDNGAEDSGDTEDELRRVAEQKEHRLPPGQEENGEDPYAGSTDENTDSEEHQEPP
|1790 | 1800 | 1810 |1820 | 1830
1JNX | 15 98 824 7 ASWKELSSFTLG TGVHPIVWQPDAWTEDNGFHAIGQMCEAPWTREW-VLDSVAL
1JNX |15988247 ASWKELSSFTLG TGVHPIWVQPDAWTEDNGFHAIGQMCEAPWTREW-VLDSVAL
XRCCI | 9954649 DLPVPELPDFFQGKHFFLYGEFPGDERRKLIRYVTAFNGELEDNMSDRVQFVITAQEWDPSFEEA
| 1850
1JNX | 15 9 8 824 7 YQCQELDTYLIPQIP-
1JNX | 15988247 YQCQELDTYLIPQIP-
XRCC1 | 995464 9 YSCNEKQKLLPHQLYGWPQA
Risk of Breast Cancer
Although most of the identified BRCAI mutations have been designated as benign
polymorphisms, many clinically validated ones lead to cancer predisposition. The majority of
mutations lead to protein products missing one or more BRCT domains (Yu, 2004). Mutations in
this region cause truncation of the domain(s) resulting in partial or complete loss of protein
function (Varma, 2005). Commonly removal of these domains generally leads to an increased
incidence of tumors. Less severe substitutions and missense mutations disrupt the secondary
structure. BRCAI & BRCA2 mutations only account for a small percentage of the total
population affected by the disease. Other genetic components such as p53, NBSl, ATM may
contribute to extended cell growth.
Risk is significantly altered depending upon the number of mutations in a single gene or
across multiple genes (BRCA2, CHEK2, RAD51). Mutations in BRCAI are inherited in a pattern
of autosomal dominance (Hall, 1990) / (Information about Cancer, 2006). BRCAI related cancers
tend to occur along familial [verse sporadic] lines.
There is also a portion of the population
without any BRCAI mutations having extremely high incidences of cancer.
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BRCAI type cancer affects 1 in 800 people in the US population (Le, 2003).
Approximately 1 in 500 to 1000 people are carriers of at least one BRCAI mutation (Genetics,
2002). Genetically linked (germline) breast cancer only accounts for 5% of breast cancer in the
general population and upwards of 15-20% for families with a strong history. Women with a
family history of both breast and ovarian cancers have much higher incidence of 60-80% breast
cancer (Nathanson, 2001 ) and 40% ovarian cancer.
The relative risk of developing breast cancer peaks at age 35 then decreases slowly for
people without a BRCAI mutation. The cumulative risk is estimated at 65% by age 70
(Antoniou, 2003). This means younger women are more likely to get the disease (Table 16).
During a woman's lifetime there is about a 1 in 7 chance of developing a form of breast cancer.
A 2002 study looking at 933 ovarian cancer patients found hereditary patients survived on
average longer than non-hereditary patients. Chemotherapy and radiation were more effective in
these patients and they tended to have a lower recurrence rate (Boyd, 2000).
Men with germline mutations have an estimated 6% risk of breast cancer. This is about
80 times greater than the general population (Nathanson, 2001 ).
Table 16 - Cumulative Breast Cancer Risk
The cumulative risk of contracting breast cancer decreases with age regardless of population. (Easton,
1995)
Age Cumulative Risk
30 years 3%
40 years 20%
50 years 51%
60 years 54%
70 years 65%
In 70-80% of BRCA /-mutated breast cancers, a mutated TP53 (tumor suppressor gene) is
also found. This compares to a 30% mutation rate in TP53 alone where a wildtype BRCAI is
present (Hartman, 2002). p53 has the ability to provide nucleotide excision repair in the absence
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of GADD45. This finding suggests the high incidence of mutated p53 in the presence of mutated
BRCAI inhibits the alternate repair pathway.
BRCAI Cancer Causing Mutations
The majority of BRCAI mutations are unique to a person or family in that they are not
common throughout the general population. Mutations predisposing cancer are inherited in a
pattern of autosomal dominance.
"Founder
mutations"
occur when a population experiences an elevated level of
inbreeding due to geographic isolation. Over time, rare mutations recur becoming more common
in the general population (Table 17). Population examples of this phenomenon are Jewish,
Swedish, Icelanders, Netherlands (Holland). In the Pakistani population, first cousin marriages
have a higher incidence of breast cancer. This supports the founder mutation theory. They also
have the highest rate of breast cancer among any Asian population (Liede, 2002). The incidence
of detection of founder mutations increases over 18x when a family has a history of breast or
ovarian cancer (Tonin, 1998).
Mutations occur throughout the BRCAI sequence but modifications at the terminal ends
are most damaging to function (Table 1 8). Isolating a specific cancer causing variant is a difficult
task. For example, the R1699W mutation found exclusively in Western European populations is
associated with cancer while the R1699Q effect is unclear (Vallon-Christersson, 2001). On the
contrary, M 16521 is frequently observed in cancer patients, however, laboratory testing concluded
it does not cause structural deformities (Humphrey, 1997).
The Ashkenazi Jewish population is the most closely studied population and perhaps one
of the most impacted by BRCAI mutations. Approximately 2% (1 in 100) of Ashkenazi Jews
carry a mutation in either BRCAI or BRCA2 (Struewing,
1997). Few mutations outside the
185delAG and 5382insC founder mutations are present within the population (Phelan, 2002).
People with either the BRCAI 185delAG or BRCA2 6174delT mutation have a 36% chance of
developing the disease. The occurrence rate is three times higher than in the normal population
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(Fodor, 1998). These mutations significantly compromise structural integrity leading to protein
product inactivation and cancer.
185delAG is the most frequently occurring mutation and spans all nationalities. Some
studies have shown male patients with the 185delAG mutation are twice as likely to develop
prostate cancer (Giusti, 2003).
Second to 185delAG is the BRCT reading frame-shift mutation 5382insC. This mutation
is seen across equally as many population groups but incidence ranges much higher in the Polish
population. In this group, 5382insC accounts for over 50% of mutations followed by C61G at
20% (Gorski, 1003). In Italian families, the 5382insC mutation is coupled almost exclusively
with a combination of ovarian and breast cancers (Santarosa, 1999).
The R71G, G1706E, A1708E and 589delCT mutations are found almost exclusively in
the Spanish population. Interestingly, heavy Spanish influence in Latin America and the
Caribbean has transported 1708E across the Atlantic. The other three mutations are reported far
less frequently in this portion of the world. These mutations along with 185delAG account for
50% of Spanish decent linked mutations (Diez, 2003).
Some nonsense mutations cause skipping of one or more exons producing a truncated but
functional polypeptide. This event is called Nonsense-mediated Altered Splicing (NAS). The
exon skipping occurs when a splicing enhancer (in the coding sequence) is altered through a
missense or nonsense mutation (cSNP) (Liu, 2001 ). As an example, the Q1694X mutation causes
skipping of exon 18. This mutation has been reported in 10 patients (BIC). NAS only occurs in
cases where the exon skipped contains a multiple of three nucleotides (Liu, 2001 ).
Native North American women exhibit extremely high incidence of gallbladder, cervix
and kidney cancers but far lower breast cancer rates. To date, only two population specific
mutations have been identified in Native Americans. The two mutations 1506delA and 1510insG
occur in exon 11 at codon 464 (Liede, 2002). Both lead to a premature stop codon found
exclusively in Native North Americans.
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Table 17 - Founder / Population Specific Mutations
Some mutations have become isolated to a specific population or ethnic group such as R1699W commonly
found in Western Europeans. Other mutations such as 185delAG or 5382insC are the only mutations found
within the Jewish population.
Mutation Exor Population Citation
M1V/A1200 i French (Rostagno, 2003)
1 85delAG 2 Jewish (Phelan. 2002)
185delAG 2 Indian (Kumar, 2002)
185delAG 2 Italian (Caligo. 1996)
185delAG 2 Spanish (Diez, 2003)
185delAG 2 Canadian (Simard, 1994)
1 85delAG 2 Chilean (Mew, 2002)
C39R 3 Czech (Machackova, 2001)
T243C 3 French (Rostagno, 2003)
252del4 3 Italian (Caligo, 1996)
IVS5+3A>G 1-5 Belgian (Claes. 2004)
IVS5+3A>G 1-5 Belgian (Claes, 2004)
C61G 5 Czech (Machackova, 2001)
C61G 5 Polish (Byrski, 2003)
C64R 5 Italian (Caligo, 1996)
R71G 5 Spanish (Diez, 2003)
589delCT 8 Spanish (Diez, 2003)
589delCT 8 Chinese (Tang, 1999)
Q356R Canadian (Tang, 1999)
Q356X Chinese (Tang. 1999)
1499insA Italian (Caligo, 1996)
2080insA Pakistani (Liede, 2002)
N723D African Arm (Olopade, 2003)
2418deIA African Amt (Fetzer, 1999)
2478insG Belgian (Claes, 2004)
2594delC Danish (Bergthorsson, 2001 )
2800delAA Scottish (Scottish, 2003)
Q957X Swiss (Garvin, 1997)
3761delGA Czech (Machackova, 2001)
P1150S Chinese (Tang, 1999)
K1183R Swiss
E1221X Belgian (Claes. 2004)
3819del5 Czech (Foretova, 2004)
3819del5 Polish (Byrski, 2003)
P1238L Jewish (Phelan, 2002)
3871del4 Swiss (Garvin. 1997)
3889delAG Pakistani (Liede. 2002)
S1218C Scottish (Scottish, 2003)
4153delA Polish (Gorski, 2000)
Mutation Exor Population Citation
IVSI2-l643dt 1-12 Dutch (Verhoog, 2001)
4148del4 12 Pakistani (Liede, 2002)
4248delAG 12 Pakistani (Liede, 2002)
R1443T 13 Fr. Canadiar (Tonin. 1998)
IVSI4-1G>A 1-14 Pakistani (Liede. 2002)
C449 1 T 14 French (Rostagno. 2003)
4572del22 14 Jewish (Phelan, 2002)
Q1458X 14 Chinese (Tang. 1999)
S 15 121 15 Jewish (Phelan. 2002)
D1546N 15 Jewish (Phelan, 2002)
4873delCA 16 Italian (Caligo. 1996)
4875delCA 16 Italian (Caligo. 1996)
D1692N 17
X1694X 18 Western Eui (Liu, 2000)
C1697R 18 Danish (Bergthorsson. 2001)
G1706E 18 Spanish (Diez, 2003)
A1708E 18 N.W. Spain (Diez. 2003)
5283insC 20 Turkish (Balci, 1999)
5382insC 20 Swiss (Garvin, 1997)
5382insC 20 Jewish (Phelan. 2002)
5382insC 20 German (Dong. 1998)
5382insC 20 Italian (Santarosa, 1999)
5382insC 20 Canadian
5382insC 20 Polish (Byrski, 2003)
5385insC 20 Czech (Foretova. 2004)
5385insC 20 Russian (Gayther, 1997)
5454delC 22 Philippino (Matsuda, 2002)
R1835X 24 European (Dong, 1998)
C5622T 24 Turkish (Balci. 1999)
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Table 18 - Cancer Causing Mutations
Mutations with strong links to cancer are listed in this table. To qualify as a 'cancel
family history of both breast cancer and the specific mutation must exist.
'
mutation, a strong
Mutation Exon Result Citation
C24R 2 Alter folding (Vallon, 2001)
C39S/Y 3 Slight structure alteration, weaken binding (Vallon, 2001)
C44F 3 Alter folding (Vallon, 2001)
C47G/F 5 Alter folding (Vallon, 2001)
C61G 5 Slight structure alteration, weaken binding (Vallon, 2001)
C64G/R/Y 5 Slight structure alteration, weaken binding (Vallon, 2001)
Q356R 11 Unclear since not located in domain. (Dunning, 2000)
P871G 1 1 Unclear. (Dunning, 2000)
S1613G 16 Unclear. (Dunning, 2000)
D1692Y 17 Destabilize core (Williams. 2003)
Q1694X 18 Skip exon 18 (Liu. 2001)
E1694K 18 Reduce BACHI binding. (Liu, 2001)
F1695L 18 Reduce BACHI binding. (Liu, 2001)
V1696L 18 Reduce BACHI binding. (Liu, 2001)
C1697R 18 Destabilize core (Williams, 2003)
C1697R 18 Unknown. (Vallon, 2001)
R1699W 18 Destabilize core (Williams, 2003)
A1708E 18 Destabilize core (Williams, 2003)
S17I5N 18 Loss of activity (Vallon, 2001)
S1715R 18 Charge change, destabilize core. (Williams, 2003)
G1738E 20 Loss of activity (Vallon, 2001)
H1746D 20 Unknown. (Liu, 2001)
P1749R 20 Charge change, destabilize core. (Williams, 2003)
M1775R 21 Causes sterical clash. Disrupts BRCAI -CtlP (Varma, 2005)
W1837X 24 Truncation (Vallon. 2001)
BRCAI Conservation in Other Species
Studying BRCAI conservation in other species was far easier than humans alone as many
complete sequences are available. All comparisons were conducted using the Human BRCAI
protein sequence (AAA73985) generated from the BRCAI nucleotide sequence U 14680. To
begin, I BLASTed the primary sequence against the full organism database. This produced 200
results with E-values approaching 0.0 from the NCBI non-redundant protein database using
BLOSUM62 and 45. Hand curating these yielded 53 unique species with significant homology.
I then re-blasted against the 30 available individual organism databases. The 1853 residue
BRCAI sequence yielded no homology in viruses, Achaea, bacteria or arthropoda including
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Poteome, Aquifex aeolicus, Bacillus subtilis, C.elegans, Drosophila, E.coli, HIV, Methanococcus
jannaschii, Ovis aries, Plasmodium falciparum, and Saccharomyces cerevisiae.
Table 19 - BRCAI N-terminal Homology
Strict conservation exists in the N-terminal region of BRCAI throughout all Animal Chordata. The C3HC4
RING (blue) is highly conserved with no variation in position. Sequences are labeled with species and
NCBI Gl number.
Human | 555932
Chimpanzee | 38503185
Gorilla|48479022
Orangutan | 48479020
Chinch Monkey | 48479018
Mouse | 4097808
NorwayRat | 6 978573
Dog| 61740517
Cowj 30466260
Opossum| 77020291
Opossum j 62638180
Chickenj 15081211
Xenopusj 15991720
| 10 I 20 | 30 | 40 | 50
MDLSALRVEEVQNVINAMQKILECJPICJLELIKEPVSTKdD^IFBKFeflLKLLNQK
MDLSALRVEEVQNVINAMQKILE|PI|LEt.IKEPVSTKCpHllFCKFC^LKLLNQK
-
-MDLSALRV-EVQNVINAMQKILElpi^ELIKEPVSTKmHIFCKFiaiLKLLNQK
MDLSAVRVEEVQNVINAMQKILE^PICLELIKEPVSTKCptdlFqKFCMLKLLNQK
MDLSAVTlVEEVQlWINAMQKILEGPICLELIKEPVSTKdDyiFCRFb^LKLLNQK
^C)LSAVQIQEVQIWLHAMQKI_E|pIapELIKEPVSTKCpH!IFclKFPf_,KLLNQK
MDLSAVRIQEVQNVLHAMQKILEQPICfLELIKEPVSTQCpHIFclKFCMLKLLNQK
MDLSADRVEEVQNVLNAMQKILEqPICLELIKEPVSTKCp^IFdKFO^LKLLNQR
MDLSADHVEEVQNVLNAMQKILEdPICpELIKEPVSTKCpHlFckFCkLKLLNQK
MDLPTVTIEEVKNVLIGMQKILEb;PiqLELIKEPVSTTqpHjIFQRFC)ILKLLSKK
ESKEMDLPTVTIEEVKNVLIGMQKILEqPICpELIK-PVSTTcb^IFCRFdMLKLLSKK
MDLSVIAIGDVQl^LSAMQKWLECiPVCpDVIKEPVSTKqpHiVFcjRFCiMFKLLSRK
MTCSRMDIEGICSVIS\mQKN_EBPIcLELMKEPVATK(3taH;IFCKFOMLQLLSKK
Human | 555932
Chimpanzee | 38503185
Gorilla|48479022
Orangutan | 48479020
Chinch Monkey | 484 7 9018
Mouse|4097808
NorwayRat | 6 978573
Dog|61740517
Cow| 30466260
Opossum | 77020291
Opossum| 62638180
Chickenj 15081211
Xenopusj 15991720
| 70 | 80 | 90 | 100 | 110
KGPSQGPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLEYANSYNFAKKENNSPE
KGPSQQPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLEYANSYNFAKKENNSPE
KGPSQCPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLEYANSYNFAKKENNSPE
KGPSQCPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLQYANSYNFAKKENNSPE
KGPSQCPLdKNDITKRSLQESTRFSQLVEELLKIIHAFQLDTGLQFANSYNFAKKENHSPE
KGPSQCPLCKNEITKRSLQGSTRFSQ_AEEL_RIMAAFE_DTGMQLTNGFSFSKKRNNSCE
KGPSQCPLCKNEITKRSLQGSARFSQLVEELLKIIDAFELDTGMQCANGFSFSKKKKSSSE
KGPSQCPLCtCNDITKRSLQESTRFSQLVEELLKIIHAFELDTGLQFADSYNFSKKENNSPE
KGPSQCPLCKNDITKRSLQESTRFSQLVEELLKIIHAFELDTGLQFANSYNFSRKEDNSPE
KGPSQCPLCKNNITKRSLRESTRFNQLVEGLLKTIRAFELDTGFQFSNTQDFSKWERRTPE
KGPSQCPLCKNNITKRSLRESTRFNQLVEGLLKTIRAFELDTGFQFSNTQDFSKWERRTPE
KKG-QCPLCKTEVTKRSLKENSRFKQLIEGLLEAISAFELDTGVKFLSSRYFPKTSTEVAT
KKG-PCPLCKTEVTRRSLQESHRFKLLVEGQLKIIKAFEFDSGYKFFPSQEHTKGLDSTIE
As would be expected, significant homologous pairs were found in Chimpanzee, Gorilla,
Orangutan and the Chinch Monkey (Table 19, Table 20). However, mouse, rat, dog, opossum,
chicken and frog exhibited homology only slightly less than primates. Unfortunately, many other
species'
sequences did not include amino acids in the N-terminal region. This may be due to the
entire gene not being sequenced or a lack of conservation in the N-terminus.
I then blasted each terminal sequence against the entire database to find conservation at
the endpoints and also in other genes. The 1 16 amino acids of the RING domain exhibited
identical homology to Chimpanzee and Gorilla. The RING domain is essentially 100%
conserved in this region with only a few minor mutations occurring in the Orangutan and Chinch
Monkey sequences.
57
Table 20 - BRCAI C-terminal Homology
The BRCAI C-terminus exhibits less homology than the N-terminus. Primates display near 100%
homologous sequences while other Chordata . Highly conserved backbone amino acids exit at 1699-1704,
1774, 1775, 1835 and 1838 as pictured in blue. Sequences are labeled with species and NCBI Gl number.
Human | 555932
Chimpanzee | 38503185
Gorilla|48479022
Orangutan| 48479020
Chinch Monkey | 48479011
Mouse | 4097808
NorwayRat | 6 97857 3
Dog|61740517
CowJ30466260
Opossum| 77020291
Opossumj 62638180
Chickenj 15081211
Xenopusj 15991720
| 1640 |1650
-
-ASTERVNKRMSMW
ASTERVNKRMSMW
ASTERVNKRMSMW
ASTERVNKRMSMW
ASTERVNKRMSLW
SSEERADRDISMW
SPKERAERDISMW
SSTRGVNKRISMVA
SSTERSKKRLSMVAJ
KKGGTGNRKISLVS j
KKGGTGNRKISLVs!
hnvagkenaassgttcrtemsivaI
FKSPWSSRRNLSFVAl
| 1660 | 1670 | 1680
.tpeefmlvykfarkhhitltnliteetthwm
.tpeefmlvykfarkhhitltnliteetthwm
.TPEEFMIjVYKFARKHHITLTNLITEETTHWM
iTPEEFMLVYKFARKHHITLTNLITEETTHWM
TPEEFMLVYKFARRYHIALTNLISEETTHWM
.TPKEVMTVQKFAEKYRLTLTDAITEETTHVI I
.TPKEVMIVQKFAEKYRLALTDVITEETTHVII
ffPKEFMLVHKFARKHHISLTNLISEETTHVIM
.TPKELMLVQKFARKHHVTLTNLITEETTHVIM
.TPKENMLVQKFARKTHSTVSHQITEGTTHVIM
.TPKENMLVQKFARKTHSTVSHQITEGTTHVIM
[QSEHLMVQKFARKTQSTFSNHITDGTTHVIM
.NQCEMALVQRFSKTTQSILSSRITDSTTHVIM
Human | 555932
Chimpanzee | 38503185
Gorilla|48479022
Orangutan | 48479020
Chinch Monkey | 4847901
Mouse | 4097808
NorwayRat | 6 978573
Dog| 61740517
Cowj 30466260
Opossum| 77020291
Opossumj 62638180
Chickenj 15081211
Xenopus| 15991720
|1690 11700 |1710 |1720 | 1730 | 1740
ktdaefvce^by|lgiaggkwwsyfwvtqsikerkmlnehdfevrgdwngrnhqgp
ktdaefvcertlkyfilgiaggkwwsyfwvtqsikerkmlnehdfevrgdwngrnhogp
ktdaefvcertlkyblgiaggkwwsyfwvtqsikegkmlnehdfevrgdwngrnhqgp
ktdaefvcertlkyfpgiaggkwwsyfwvtqsikerkmijnehdfevrgdwngrnhqgp
ktdaefvcertlkyflgiaggkwwsyfwvtqs ikerkmlnehdfevrgdwngrnhqgp
ktdaefvcertlkyflgiaggkwivsyswwrsiqerrllnvhefevkgdwtgrnhqgp
ktdaefvcertlkyflgiaggkwivsyswviksiqerkllsvhefevkgdwtgsnhogp
ktdaefvcertlkyslgiaggkwwsyfwvtqsikerkildehdfevrgdwngrnhqgp
ktdpefvcertlkyf-lgiaggkwvvsyfwvtqsikegkmi.dehdfevrgdvvngrnhqgp
ktdaefvcertlkyf;lgiaggkvfwsflwwqsfkegkmlpecdfevrgdvingrnhrgp
ktdaefvcertlkyflgiaggkwwsflwwqsfkegkmlpecdfevrgdvingrnhrgp
ktdeelvcertlkyftgiagrkwwsyqwiiqsfkegrildeehfevkgdvingrnhqgp
ktdaelvcertlkyfiqgiasrkwwsyewwqsfregqildeydfevkgdvingrnhrgp
Human| 555932
Chimpanzee | 38503185
Gorilla|48479022
Orangutan| 48479020
Chinch Monkey | 4847901:
Mouse | 4097808
NorwayRat | 6978573
Dog| 61740517
Cowj 30466260
Opossum | 77020291
Opossumj 62638180
Chickenj 15081211
Xenopusj 15991720
| 1750 |1760 |1770
"'
| 1 7 8 0 | 1790 | 1800
kraresqdrkifrgleiccygpftftflptdqlewmvqlcgajsvvkelssftlgtgvhpivv
kraresqdrkifrgleiccygpft^mlptdqlewmvqlcgaiswkelssftlgtgvhpiw
kraresqdrkifrgldiccygpftpiptdqlewmvqlcgajswkelssftlgtgvhpiw
kraresqdrkifrgleiccygpftfelmptdqlewivqlcgaswkelssftlgtgvhpiw
krarespdrkifrgleiccygpft^yjptdqlewmvqlcgaswkelssftlgtgfhpiw
rrsresre . klfkglqvyccepftti^pkdelermlqlcqaswkelpslthdtgahlwi
rrsresqe . klfeglqiyccepft^pk_elermlqlcgaswkelplltrdtgahpivl
kraresqd-kifrgleiccygpftnm'ptdqlewmvhlcgaiswkepslftlskgthpvw
kraresrdkkifkgleiccygpftnmptdqlewmvqlcgajswkepssftpdqgthpwv
eraresqgmkifrgleiccygpftd^stdqlewmvqlcgaswkkpsslrfrvgsspvw
eraresqgmkifrgleiccygpftdistdqlewmvqlc^swkkpsslrfrvgsspvw
krarqspaekifkdfeicccgpftd|ttghlewivelc&wkqi.hlfthkvnstavw
rr.qrt,gsdglllidfeicffgsftdmtlddlewmvsec(3atwkklqffkkkhnvtslvi
Human | 555932
Chimpanzee | 38503185
Gorilla|48479022
Orangutan | 48479020
Chinch Monkey | 4847901
Mouse | 4097808
NorwayRat | 6 978573
Dog| 61740517
CowJ30466260
Opossum| 77020291
Opossumj 62638180
Chickenj 15081211
Xenopus | 15991720
| 1820 | 1820 | 1830 | 1840 | 1850 | 1860
VQPDAWTEDNGFHAIGQMCEAPWTREWVL'DSVALYQCQELDTYLIPQIPHSHY
VQPDAWTEDNGFHAIGQMCEAPWTREWVLDSVALYQCQELDTYLIPQIPHSHY
VQPDAWTEDNGFHAIGQMCEAPWTREWVL'DSVALYQCQELDTYLIPQIPHSHY
VQPDAWTEDNGFHAIGQMCEAPWTREWVIi'DSVALYQCQELDTYLIPQIPHSHY
;
vqpdawtedngfhaigqmceapwtrewvldsvalyqcqeldtylipqiphshy
vqpsawtedsncpdigqlckarlvmwdwftslssyrcrdldaylvqnitcdssepqdsnd
vqpsawtedndcpdigqlckgrlvmwdwHdsisvyrcrdldaylvqnitcgrdgsepqds
VQPDAWTEDSGFHAIGQMCEAPWTREWVLDSVALYQCQELDTYLIPQIPRTAADS
VQPDAWTEDAGFHVIGQMCEAPWTREWVLDSVALYQCQELDTYLVP
VQPDAWEDDSSFQEIGLVCEAPWTREWVLDSVACYQRQELDTYLISQTSPSLC
VQPDAWEDDSSFQEIGLVCEAPWTREWVLDSVACYQRQELDTYLISQTSPSLC
VQPDAWMEGTSYEAIQRKNNVAWTREWVLDSVACFECQELDAYLVSQD
VOPDASTEVRDYTEIRKKHKALWT1EWLMDSVATYRLQKFDAYLA
In the remainder of the species the major cysteine and histidine binding sites are
completely conserved. The most N-terminal
RING is strictly conserved especially at the helix
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and beta-strands. Slightly less homology exists throughout the remaining sequence with most
variation in exons 5 and 6.
Similarly, the BRCT is also highly conserved with all four primates almost 100%
identical while other species lose homology approaching the terminal end. The linker region
between the two repeats is the least conserved portion. Amino acids along the surface of the
tandem repeat cleft junction are highly conserved. See Table 20 codons 1699-1704 and 1774-
1775, 1835 and 1838.
BRCAI Central Region Conservation
To demonstrate conservation in the central region of BRCAI I blasted the exon 1 1 portion
of the sequence. This region ranges from residue 263 to 1405. Conserved areas are found
sporadically through the range but are usually no longer than five amino acids in length. These
highly conserved areas are typically separated by wide areas of divergence.
In exon 1 1 I found three conserved areas. The first is the 823-900 regions listed in Table
21. This appears to be the most highly conserved region with 15 closely packed amino acids
found in all 12 species. Unfortunately there are no known binding or phosphorylation sites in this
region.
Other conserved areas are the 1 100-1250 and 1350-1400 ranges. Within these areas are
mammalian conserved Serine 988, 1387, 1457, 1524 and Tyrosine 1394. These are well known
phosphorylation sites for ATM and A TR (Okada, 2003).
Table 21 - BRCAI Exon 11
The central region exhibiting the highest specie homology is located at amino acids 823-900 (Human). The
sixteen codons pictured in blue display a compact region of conservation.
Human | 555932
Chimp| 38503185
Gorilla | 48479022
Orang. |48479020
ChinchJ48479018
Mouse | 4097808
NorwayRat | 6 978573
Dog|61740517
CowJ30466260
Opossum| 77020291
Opossumj 62638180
Chickenj 15081211
Xenopus | 15991720
| 829 | 830 | 840 | 850 | 860 | 870 | 880
FKYPLGHEVN-HSRETSIEMEESELDAQYLQNTFKVSKRQSFAPFSNPGNAEEECATFSAHSGSLK
FKYPLGHEVN-HSRETSIEMEESELDAQYLQNTFKVSKRQSFALFSNPGNPEEECATFSAHCRSLK
FKYPIjGHEVN-HSRETSIEMEESELDAQYLQNTFKVSKRQSFALFSNPGNPEEEigATFSAHSRSLK
FKYPLGHEVN-HSQETSIEMEESELDTQYLQNTFKVSKRQSFALFSNPGNPEEErJATFSAHSRSLK
FKYPLGSEVN-HSQETSIEIEESELDTQYLQNTFKVSKRQSFALFSNPGNPEEEeATFSAHSRSLK
LKPPLRHALN-LSQEK-VEMEDSELDTQYLQNTFOVSKRQSFALFSKPRSPQKDb AHSVPSK
FKHPIjRHELN - HNQET - I EMEpSELDTQYLQNTFQVSKRQSFALFSKLRSPQKDqTLVGARSVPSR
FWPLTCKDN-HTQETSIEMEESELDTQCLRNMFKVSKRQSFALFSYPRDPEEDrivTVCPRSGAFG
FQDLLGHDINYVIQETSREMEDSELQTQYLQNTFKASKRQTFALFSNPGNPQKEEATVFAHSGSLR
LRGLMRQGVK-NASETTTEMEDSELDTQYLQNTFKRSKRQTFALGS SPRQEGMKPCAISQALH
LRGLMRQGVK-NASETTTEMEDSELDTQYLQNTFKRSKRQTFALGS SPRQECMKPCAISQALH
FRIGKSPMAK-NASEFTMEAEDSELDMQYLRNIFRSSKRQSFSLYP TPMKACTTDDVASEKLN
FRIGKSPMAK-NASEFTMEAEDSELDMQYLRNIFRSSKRQSFSLYP--
-TPMKACTTDDVASEKLN
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BRCAI Mouse Model
Mus musculus BRCAI maps to chromosome 1 1 at 60.5cM adjacent to Com2 (Corneal
disease 2), see Figure 16. Similar to humans, mouse BRCAI is in close proximity to the adjacent
to NBRI gene. A separation of less than 300bp allows BRCAI expression to be driven by a
shared promoter with NBRI (Whitehouse, 2004). Mouse BRCAI operates in similar pathway to
human BRCAI however, some significant functional differences occur in the presence of a
haploid gene.
Mouse BRCAI homolog is syntenic with Human BRCAI meaning the gene order is
conserved over evolutionary distances. In terms of identity, approximately 87% of exons are
homologous to BRCAI while at the amino acid level identity drops to 55%.
Beyond sequence homology it is difficult to study the effect of single amino mutations in
mice. Mouse models have been tricky to develop since homozygosity is lethal during embryonic
development and heterozygous mice are not cancer prone. Heterozygous mice are normal
functioning at 1 1 months and tumor free. However, when a sequence mutation is introduced on
one allele while the other allele is deactivated they die shortly after conception. BRCAI deficient
mice are unable to repair double-strand breaks by homologous recombination. These mice are
hypersensitive to IR and are unable to carry out transcription repair of damaged DNA
(Whitehouse, 2004).
Mice with exon 5 & 6 deletions exhibit severe developmental defects before reaching
mortality at 7 days into gestation. This may be a consequence of lower cyclin-E levels at the
Gl/S transition resulting in slower cell growth (cell proliferation) and embryo size. Early
embryonic arrest suggests exons 5 and 6 are responsible for cell proliferative burst (Haken, 1996).
Mice with exon 1 1 deletion survive to about 13 days but exhibit spina bifida and other
neuroepithelial defects (Gowen, 1996). These cells have an intact Gl/S phase checkpoint but a
defective G2/M checkpoint. Embryos surviving longer than 13 days have extensive
chromosomal abnormalities such as multiple centrosomes. This suggests BRCAI not only
60
regulates cell cycle checkpointing but also genomic stability through centrosome replication (Xu,
1999). Interestingly, a combination of homozygous exon 1 1 deletion and heterozygous removal
of a p53 allele allowed for full embryo development. However, mice with this chromosomal
abnormality began to develop tumors in 6-12 months after birth (Xu, 2001 ).
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Figure 16 - Mouse Comparative Map
Mouse BRCAI maps to chromosome 1 1 adjacent to the Corn2 and NBRI at 60.50cM. Source: Mouse
Genome Informatics
Rattus norvegicus
Similar to mouse, Rattus nonrgicus shares approximately 83% sequence similarity at the
terminal ends. Rat codons 1589-1817 map to the BRCT 1 646-1959 region in humans.
To study BACHI binding functionality with Rat BRCAI and investigate structural
different, the 1L0B model was created with BRCAI bound to p53. Structural analysis shows rat
hydrophobic residues Argl645, Leu 1651, and Ala 1654 are conserved between human and rat and
hydrogen bond contacts Argl645, Asp 1785, Argl727 and He 1626 occur at same positions (Joo,
2002).
Human cancer causing mutations E1694K, F1695L, and V1696L were replicated in rat at
Glul640, Phel641 and Vail 642. Protein products with a single mutation caused a deformed
BRCT (33 sheet. This resulted in 30-50% less BACHI binding activity (Joo, 2002). Rat N17I9R
is a less severe disruption as it falls on a turn and not a helix of sheet.
Canis familiaris
Overall, Canine BRCAI shares 71% sequence similarity with the human homolog. At
both N and C-terminus the identity rises to 84%. The central region, including exon 1 1 has about
70% homology but the longest 'domain' is no more than 21 acids in length (Szabo, 1996).
Canine BRCAI is relatively the same length as the Human strand with only forty-five additional
bases due to small insertions.
Little structural comparison research has been done on the consequences of mutations
carried into the canine sequence. However an interesting repeat occurs in the central region. At
(human) 1758, Canine BRCAI contains an 18bp duplication of the previous five amino acids.
This rare mutation is well conserved against other Canine database samples.
Table 22 - Human-Canine duplication
A five amino acid sequence duplication occurs in canine at 1758. This duplication is highly conserved
throughout all NCBI Canine samples.
| 1740 | 1750 |1760 | 1770 | 1780
Human | 555932 DFEVRGDWNGRNHQGPKRARESQDR KIFRGLEICCYGPFTNMPTDQLEWMVQLC
Dog|61740517 DFEVRGDWNGRNHQGPKRARESQDFjESQDRKIFRGLEICCYGPFTNMPTDQLEWMVHLC
Drosophila
Table 23 - Human-Drosophila
Similar to Animal Chordata, Drosophila conserves the C3HC4 Zinc-finger at critical site C24, C27, C39,
H41, C44, C61, and C64 (blue). Other conserved amino acids are shown in grey.
1 20 | 30 1 40 | 50 1 60
1JM7 | 15988069 AMQKILEEPICLELIKEPVSTK-CDHIFCKFOMLKLLNQKKGPSQCPLCKNDIT-KRSLQESTRF
DRING|2388783 SLHSELMCPICLDMLKKTMTTKECLHRFCSDCIVTALRSGNKECPTCRKKLVSKRSLRADPNF
The Drosophila RING sequence contains large gaps of sequence divergence with only 34%
amino acid identity to the human homolog. However, all eight amino acids composing the Zinc
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finger loops are conserved. At the C-terminal about the same homology exists but significant
binding sites and turns are not distinguishable between the two sequences.
Overall Conservation
Primate conservation ranged between 98-100% within the RING and C-terminal regions.
Over the entire sequence homology dropped to only 96% within all coding regions. Other species
express more variation overall but maintained high scores in the terminal regions (Table 24).
The near 100% conservation of binding sites suggests a possibility of evolutionary
conserved orthologs. The high identity expressed in the terminal ends appears to have evolved
under negative selection which is why they are almost identical. On the contrary, the high
variability in the central region shows diversification or positive selection.
Table 24 - Percent Identity to Human BRCAI
Primate BRCAI is nearly 100% conserved among all species. Both terminal regions are conserved almost
equally in each species though overall conservation drops steadily outside Primates.
BRCN BRCT Overall
Chimpanzee 100 100 98
Gorilla 100 100 98
Orangutan 99 99 97
Chinch Monkey 99 99 96
Mouse 80 83 55
Rat 86 83 55
Dog 91 84 74
Cow 91 89 71
Opossum 89 84 45
Chicken 62 62 29
Xenopus 60 53 34
Drosophila 34 34 26
Comparing Table 19 and Table 20, the BRCN region conserves more mutations than the
BRCT-terminal. Patient derived mutations I15L, 142V and D67E are frequently observed in the
less evolved mammals and amphibians. In BRCT, F1695L. H 1672Q. G1764D area few mutation
conserved only between the Chicken and Xenopus sequences. These mutations are attributed to
SNPs.
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There are five conserved regions in BRCT, N-terminus/Pl, ccl/p2, P3, P4/oc3 and the C-
terminus. Most variation occurs at a2 helix and surface loops between Alphal & Beta2 (CI ) and
Beta2 & Beta3 (C2). Mutations in this region are unlikely to alter folding properties as the loops
are far from the backbone structure (Zhang, 1999).
Discussion
Although BRCAI is a highly studied gene and a wealth of information exists, it was
extremely difficult finding reliable and accurate research. Literature searches revealed a
considerably amount of information, however, many papers were outdated. For example, I found
numerous papers describing the same pathway but with major discrepancies. Instead of
compiling the BRCAI pathway during a few days, my research spanned several weeks
substantiating all reactions with scientific evidence.
An example of this is the role of BRCAI activation of Chkl . Protein Lounge and several
articles provide considerable evidence for this claim. However the NCBI OMIN page for
CHEK1 (approved gene symbol) does not contain a single mention of BRCAI. A 2002 paper by
Lee validates the interaction of these two proteins so it's puzzling that the official Chkl reference
does not note this information.
Furthering the confusion is pathway activation by either ATM or ATR. Some papers
discussed ATM activation of Chkl while others conclude ATR as the stimulus. It was only in
2002 that Falck's identification of both proteins as activators clarified these pathways. He
discovered that either kinase can phosphorylate Chkl and NBS1-FANCD2 substrates under
differing UV and IR conditions.
Another challenge was finding recent prediction and modeling software. Many of the
programs developed at colleges look promising but use outdated techniques or algorithms and are
often poorly documented. CBSU's LOOPP program is a good example.
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LOOPP is a 3D structure prediction program producing PDB output based on sequence
alignment. Since this program uses different scoring metrics than Swiss-Model it would make for
a good comparison. Sequence submission is through a web interface with result returned via
email. The email contains a compressed archive containing twenty text files along with DOS
executables.
LOOPP'
s documentation does not explain how to use the executables nor clearly
interpret the results.
In this research project I studied the structure and function of the proteins produced by
the BRCAI gene. An attempt was made to draw genetic relationships between cancer patients of
diverse ethnicities and geographic locations. My research found specific mutations isolated to
single populations such as Western European, Dutch, Native North Americans, and Ashkenazi
Jewish populations. Taken together, my findings suggest a strong correlation between geographic
isolation and mutation exclusiveness. Furthermore BRCAI sequence homology and mutation
conservation are exhibited among primates in addition to other species.
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Appendix A
Molscript input file for 1JNX terminus:
! MolScript v2 . 1 input file
title "BREAST CANCER TYPE 1 SUSCEPTIBILITY PROTEIN'
plot
window 38.53;
slab 27.35;
read mol "1JNX-1 ;
transform atom * by centre position atom *
by rotation
-0.620329 0.151884 -0.769495
-0.635512 -0.672322 0.379615
-0.459691 0.72451 0.513585;
set segments 2 ;
set planecolour hsb 0.6667 1 1;
coil from X1649 to X1651;
!B1
set planecolour hsb 0.6154 1 1;
strand from X1651 to X1655;
set planecolour hsb 0.5641 1 1;
coil from X1655 to X1658;
!A1
set planecolour hsb 0.5128 1 1;
helix from X1658 to X1673;
set planecolour hsb 0.4615 1 1;
coil from X1673 to X1674;
!B2
set planecolour hsb 0.4103 1 1;
strand from X1674 to X1677;
set planecolour hsb 0.359 1 1;
coil from X1677 to X1685;
!B3
set planecolour hsb 0.3077 1 1
strand from X1685 to X1690;
set planecolour hsb 0.2564 1 1
coil from X1690 to X1695;
set planecolour hsb 0.2264 1 1
coil from X1695 to X1700;
!A2
set planecolour hsb 0.2051 1 1;
helix from X1700 to X1709;
set planecolour hsb 0.1551 1 1;
coil from X1709 to X1712;
- 1
!B4
set planecolour hsb 0.1538 1 1;
strand from X1712 to X1715;
set planecolour hsb 0.1026 1 1;
coil from X1715 to X1716;
!A3
set planecolour hsb 0.0752 1 1;
helix from X1716 to X1726;
set planecolour hsb 0.05128 1 1;
coil from X1726 to X1735;
set planecolour hsb 0 11;
coil from X1735 to X1740;
end_plot
Molscript input file for 1JNX terminus:
! MolScript v2 . 1 input file
title "BREAST CANCER TYPE 1 SUSCEPTIBILITY PROTEIN1
plot
shadows on;
window 61.38;
slab 32 .30;
read mol
" 1JM7-1 ;
transform atom *
by centre position atom *;
set segments 2 ;
set planecolour hsb 0.6667 1 1
coil from Al to A7 ;
set planecolour hsb 0.6275 1 1
helix from A7 to A2 2;
set planecolour hsb 0.5882 1 1
coil from A22 to A33;
set planecolour hsb 0.549 1 1;
strand from A3 3 to A3 7;
set planecolour hsb 0.5098 1 1
coil from A37 to A42;
set planecolour hsb 0.4706 1 1
strand from A42 to A44;
turn from A44 to A45;
set planecolour hsb 0.4314 1 1
helix from A45 to A54;
set planecolour hsb 0.3922 1 1
coil from A54 to A72;
set planecolour hsb 0.3529 1 1
strand from A72 to A75;
set planecolour hsb 0.3137 1 1
2-
coil from A75 to A80;
set planecolour hsb 0.2745 1 1;
helix from A80 to A97;
set planecolour hsb 0.2353 1 1;
coil from A97 to A103;
set planecolour goldenrod;
coil from Bl to B34;
! set planecolour hsb 0.1961 1 1;
helix from B34 to B47;
! set planecolour hsb 0.1569 1 1;
coil from B47 to B74;
! set planecolour hsb 0.1176 1 1;
helix from B74 to B79;
! set planecolour hsb 0.07843 1 1;
coil from B79 to B98;
! set planecolour hsb 0.03922 1 1;
helix from B98 to B117;
! set planecolour hsb 9.714e-17 1 1;
coil from B117 to B122;
set colourparts on;
cpk in residue A123;
cpk in residue A124;
cpk in residue B12 5;
cpk in residue B12 6;
set colourparts off;
set planecolour white;
ball-and-stick require in residue A7 and backbone;
ball-and-stick in residue A10,
ball-and-stick in residue A85,
ball-and-stick in residue A96,
set colourparts off;
set planecolour darkolivegreen;
ball-and-stick require not peptide, not hydrogens and in
residue B3 6;
ball-and-stick require not peptide, not hydrogens and in
residue B43;
ball-and-stick in residue B117;
ball-and-stick in residue B110;
set linecolour cyan, linedash 4;
line position res-atom A96 CB to position res-atom B36
NE2;
line position res-atom A85 0E2 to position res-atom B43
NH1;
line position res-atom A85 OE2 to position res-atom B43
NH2;
line position res-atom A85 0E2 to position res-atom B43
NE;
-3
line position res-atom A7 CA to position res-atom B117
0D1;
line position res-atom A10 0E2 to position res-atom B110
0;
line position res-atom A10 0E2 to position res-atom B110
CA;
line position res-atom A10 1HG to position res-atom B110
CB;
set linecolour white;
set labeloffset 2 0 0; label res-atom A123 ZN "%t";
set labeloffset -5 0 0; label res-atom A124 ZN "%t";
end_plot
4-
